WO2001075087A2 - Subtilisin variants - Google Patents
Subtilisin variants Download PDFInfo
- Publication number
- WO2001075087A2 WO2001075087A2 PCT/US2001/010781 US0110781W WO0175087A2 WO 2001075087 A2 WO2001075087 A2 WO 2001075087A2 US 0110781 W US0110781 W US 0110781W WO 0175087 A2 WO0175087 A2 WO 0175087A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- seq
- nucleic acid
- sequence
- amino acids
- Prior art date
Links
- 108090000787 Subtilisin Proteins 0.000 title claims abstract description 170
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 272
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 242
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 222
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 83
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 108091005461 Nucleic proteins Proteins 0.000 claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 352
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 343
- 229920001184 polypeptide Polymers 0.000 claims description 336
- 150000001413 amino acids Chemical class 0.000 claims description 138
- 230000000694 effects Effects 0.000 claims description 124
- 102000040430 polynucleotide Human genes 0.000 claims description 116
- 108091033319 polynucleotide Proteins 0.000 claims description 116
- 239000002157 polynucleotide Substances 0.000 claims description 116
- 108090000623 proteins and genes Proteins 0.000 claims description 106
- 230000001965 increasing effect Effects 0.000 claims description 65
- 239000013598 vector Substances 0.000 claims description 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 45
- 238000006467 substitution reaction Methods 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 38
- 101710118538 Protease Proteins 0.000 claims description 36
- 108091034117 Oligonucleotide Proteins 0.000 claims description 30
- 108010020132 microbial serine proteinases Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 27
- 230000000295 complement effect Effects 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 27
- 238000009739 binding Methods 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 25
- 230000001976 improved effect Effects 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 21
- 239000003599 detergent Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 16
- 230000007935 neutral effect Effects 0.000 claims description 16
- -1 deoxyribonucleotide triphosphates Chemical class 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 9
- 230000028327 secretion Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000004807 localization Effects 0.000 claims description 5
- 108700010070 Codon Usage Proteins 0.000 claims description 4
- 229920002704 polyhistidine Polymers 0.000 claims description 4
- 238000002864 sequence alignment Methods 0.000 claims description 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 105
- 229940024606 amino acid Drugs 0.000 description 96
- 210000004027 cell Anatomy 0.000 description 76
- 108020004414 DNA Proteins 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 66
- 230000006798 recombination Effects 0.000 description 54
- 238000005215 recombination Methods 0.000 description 54
- 230000000875 corresponding effect Effects 0.000 description 44
- 238000009396 hybridization Methods 0.000 description 36
- 238000002703 mutagenesis Methods 0.000 description 28
- 231100000350 mutagenesis Toxicity 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 230000002163 immunogen Effects 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 24
- 108020004705 Codon Proteins 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 238000002741 site-directed mutagenesis Methods 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 102000035195 Peptidases Human genes 0.000 description 18
- 108091005804 Peptidases Proteins 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 17
- 239000004365 Protease Substances 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 108010056079 Subtilisins Proteins 0.000 description 14
- 102000005158 Subtilisins Human genes 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 150000007513 acids Chemical class 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 235000019419 proteases Nutrition 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000000126 in silico method Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 244000105975 Antidesma platyphyllum Species 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 235000009424 haa Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002708 random mutagenesis Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000012219 cassette mutagenesis Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000001814 protein method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010058683 Immobilized Proteins Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000007845 assembly PCR Methods 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000012361 double-strand break repair Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012269 metabolic engineering Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101100460774 Bacillus subtilis (strain 168) nprB gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 108010033272 Nitrilase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- XERQKTRGJIKTRB-CIUDSAMLSA-N Ser-His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CN=CN1 XERQKTRGJIKTRB-CIUDSAMLSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 101710173945 Subtilisin Savinase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- HXDRSFFFXJISME-UHFFFAOYSA-N butanedioic acid;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)C(O)C(O)C(O)=O HXDRSFFFXJISME-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005108 dry cleaning Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 238000000596 photon cross correlation spectroscopy Methods 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010002389 preprosubtilisin Proteins 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010066533 ribonuclease S Proteins 0.000 description 1
- 210000004358 rod cell outer segment Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 101150091813 shfl gene Proteins 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 101150105742 spoIIE gene Proteins 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
Definitions
- subtilisin has been used as additives in laundry and other detergents.
- Subtilisin has a broad specificity for proteins that commonly soil clothing, including proteins found in blood, grass, soil and many food products.
- Bacillus subt ⁇ lis subtilisin has become one of the most intensively studied and extensively engineered proteins known to date.
- a wide variety of subtilisins have been identified, and the amino acid sequences of a number of these subtilisins have been determined.
- structural investigations, including more than 100 crystal structures have revealed that subtilisins share a common active site with other serine proteases, the Ser-His-Asp catalytic triad.
- subtilisins are not only active under a variety of washing conditions, they are also stable in the presence of other detergent components and additives.
- additives may include, among other things, other enzymes such as cellulases, upases and the like.
- Subtilisin should be stable in the presence. of effective concentrations of such enzymes, and at the same time must not result in the degradation (proteolysis) of these enzymes.
- subtilisin selected for such an application should also be active under a variety of specific conditions such as high or low temperature, acid, neutral or alkaline pH, or the presence of such additives as bleaching agents. Mutations or alterations in the nucleotide or amino acid sequences which would provide these benefits are difficult to predict, and therefore difficult to engineer. Nonetheless, both random mutagenesis and targeted mutagenesis approaches have been applied to the goal of producing improved subtilisin homologues. However, attempts to develop proteases that are improved for multiple properties are hampered by the fact that random mutations are often deleterious, and attempts to rationally alter one property of an enzyme often disrupt other important existing characteristics (Patkar et al. (1998) Chem Phvs Lipids 93:95; Shoichet et al. (1995) Proc Natl Acad Sci U S A. (1995) 92:452).
- the present invention provides novel subtilisin homologues that are improved for a variety of specific properties including thermal stability, activity at low temperature, alkaline stability as well as other desirable properties and combinations of properties. These subtilisins are useful in a variety of detergent and other industrial and commercial applications.
- the present invention provides novel subtilisin homologues with improved characteristics and combinations of characteristics, including thermotolerance (thermal stability), activity at alkaline, acid and/or neutral pH, activity at ambient temperatures and activity in organic solvents.
- the invention relates to isolated and recombinant nucleic acids corresponding to polynucleotides that are novel subtilisin homologues, encode novel subtilisin proteins, hybridize under highly stringent conditions to such novel subtilisin homologues or polynucleotides encoding novel subtilisin proteins, or are fragments thereof, encoding polypeptides with endo-protease activity.
- Embodiments of the invention include polynucleotides which include a subsequence corresponding to one or more sequence selected from SEQ ID NO:l to SEQ ID NO: 130. Such polynucleotides encode polypeptides that are novel subtilisins incorporating the sequence elements of SEQ ID: 131 to SEQ ID NO: 260. Fragments of nucleic acids comprising SEQ ID NO:l to SEQ ID NO: 130 encoding 20 or more contiguous amino acids of SEQ ID NO: 131 to SEQ ID NO:260 are embodiments of the invention.
- the encoded polypeptide comprises at least 20, at least about 30, or at least about 50, or least about 75, or at least about 100, or at least about 150 contiguous amino acids of a sequence selected from SEQ ID NO: 131 to SEQ ID NO:260. In one embodiment, the encoded polypeptide is about 269 amino acid residues in length. In other preferred embodiments the encoded polypeptide is a pre-pro peptide of about 380 amino acid residues.
- such polynucleotides encode polypeptides having a diversified region between amino acid positions 55 and 227 with respect to the mature subtilisin protein, with the amino acid sequence STQDGNGHGTHVAGT-X 70 -AAL-X 74 - N-X 76 X 77 -GV-X 8 o-GVAP-X 8 5X 86 X 87 -LY-X 9 o-VKNL-X 95 -A-X 97 -G-X 99 -GS-X 1 o 2 -S-X 10 - IA-X 107 -GI ⁇ X 11 o-W-X 112 X ⁇ 3 X ⁇ 4 - ⁇ -X ⁇ 16 -M-X ⁇ 18 -IA ⁇ -X 122 -SLG-X 126 X 12 X 1 28-PS-X ⁇ 31 - TL-X 134 X 135 -ANN-X 139 -ATS-X 143 X 144 -VLVIAA-
- Nucleic acids encoding thermotolerant endo-proteases incorporating SEQ ID NOs: 3, 7, 8, 10, 12, 14, 15, 16, 18, 21 and 25 are embodiments of the invention.
- nucleic acids encoding alkaline active endo-proteases incorporating the SEQ ID NOs: 1, 17, 19, 22, 23, 24, 25, 26, 27 and 32 are embodiments of the invention.
- Nucleic acids encoding endo-proteases that are active in organic solvents, such as dimethylformamide (DMF) incorporating SEQ ID NOs: 2, 4, 5, 6, 11, 13, 20, 29, 30 and 33 are also embodiments of the invention.
- Compositions containing two or more such nucleic acids or encoded polypeptides are a feature of the invention.
- compositions are libraries of nucleic acids, preferably containing at least 10 such nucleic acids.
- Compositions produced by digesting the nucleic acids of the invention with a restriction endonuclease, a DNAse or an RNAse are also a feature of the invention, as are compositions produced by incubating a nucleic acid of the invention with deoxyribonucleotide triphosphates and a nucleic acid polymerase, including thermostable nucleic acid polymerases.
- vectors incorporating a nucleic acid of the invention include plasmids, cosmids, phage, viruses, including chromosome integration vectors.
- the vector is an expression vector.
- Cells transduced by such vectors, or which otherwise incorporate the nucleic acid of the invention are an aspect of the invention.
- the cells express a polypeptide encoded by the nucleic acid.
- polypeptides encoded by the nucleic acids of the invention are another aspect of the invention.
- polypeptides comprising the sequence elements of SEQ ID NO: 131 to SEQ ID NO:260 are an aspect of the invention.
- Such polypeptides are endo-proteases.
- Preferred embodiments include polypeptides that are endo-proteases with one or more properties selected from among: activity at ambient temperature, psychrophilic activity, thermotolerance or thermostability, activity at alkaline, acid and/or neutral pH, and activity in the presence of organic solvents, such as dimethylformamide (DMF).
- DMF dimethylformamide
- endo-protease polypeptides with desired conditional properties, such as pH dependence, temperature dependence, dependence on ionic strength, activation by ligand binding, and inactivation by ligand binding.
- the polypeptide has at least 70% sequence identity to at least one of SEQ ID NO: 131 to SEQ ID NO:260 over a comparison window of at least 20 contiguous amino acids.
- the polypeptide as at least 80%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to at least one of SEQ ID NO: 131 to
- polypeptide maintains sequence identity over a comparison window of at least 30, at least about 50, at least about 100, or at least about 150 amino acids of one or more of SEQ ID NO: 131 to SEQ ID NO:260.
- the polypeptide has an improved endo-protease activity selected from among increased thermotolerance, increased activity at ambient temperature, increased activity at alkaline pH, increased activity at acid pH, increased activity at neutral pH, and increased activity in the presence of organic solvents, relative to the subtilisin homologue polypeptide corresponding to SEQ ID NO: 261, which polypeptide has at least 70% sequence identity to at least one of SEQ ID NO: 131 to SEQ ID NO:260, over a comparison window of at least 20 contiguous amino acids.
- the polypeptide has at least 80%, at least 90%, at least 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of SEQ ID NO: 131 to SEQ ID NO:260.
- the polypeptide maintains sequence identity over a comparison window of at least about 30, at least about 50, at least about 100, or more amino acids.
- the polypeptide with an improved endo-protease activity comprises a sequence element selected from among SEQ ID NO: 131 to SEQ ID NO:260.
- Polypeptides 150 contiguous amino acids or greater in length that are encoded by a polynucleotide comprising SEQ ID NO:l to SEQ ID NO: 130, a polynucleotide encoding SEQ ID NO: 131 to SEQ ID NO:260, or a polynucleotide sequence that hybridizes under highly stringent conditions to such a polynucleotide are embodiments of the invention.
- Such polypeptides exhibit endo-protease activity.
- such polypeptides are at least about 250 amino acids, e.g., about 269 amino acids in length.
- polypeptides are at least about 350 amino acids in length, e.g., pre-pro peptides of about 380 amino acids in length.
- polypeptides of the invention with secretion and/or localization sequences are a feature of the invention, as are such polypeptides with purification sequences, including epitope tags, FLAG tags, polyhistidine tags, and GST fusions.
- polypeptides of the invention bearing a methionine at the N- terminus or having one or more modified amino acids, e.g., glycosylated, PEGylated, farnesylated, acetylated or biotinylated amino acids, are features of the invention.
- compositions that include one or more polypeptide of the invention and a detergent are an aspect of the invention.
- Methods of producing the polypeptides of the invention by introducing the nucleic acids encoding them into cells and then expressing and recovering them from the cells or culture medium are a feature of the invention.
- the cells expressing the polypeptides of the invention are grown in a bulk fermentation vessel.
- Another aspect of the invention relates to methods of producing novel subtilisin homologues by mutating or recombining, e.g., recursively recombining, the nucleic acids of the invention in vitro or in vivo.
- the recursive recombination produces at least one library of recombinant subtilisin homologue nucleic acids.
- the libraries so produced are embodiments of the invention, as are cells comprising the libraries.
- methods of producing a modified subtilisin nucleic acid homologue by mutating a nucleic acid of the invention are embodiments of the invention.
- Recombinant and mutant subtilisin homologue nucleic acids produced by the methods of the invention are also embodiments of the invention.
- nucleic acids which are unique subsequences of SEQ ID NO:l to SEQ ID NO: 130, (as compared to any subtilisin nucleic acid sequences available in GenBank, as of April 3, 2000, as exemplified by, e.g., M65086, D13157, S48754, ' AB005792, D29688, and M28537), or are unique subsequences of polypeptides selected from among SEQ ID NO: 131 to SEQ ID NO:260, (as compared to any subtilisin protein sequences available in GenBank, as of April 3, 2000, as exemplified by: P29600, P41362, P29599, P27693, P20724, P41363, P00780, P00781, P35835, P00783, P29142, P04189, P07518, P00782, P04072, P16396, P29140, P29139, P08594, P16588, P11018, P54
- the invention also provides computers, computer readable medium and integrated systems, including databases that are composed of sequence records including character strings corresponding to SEQ ID NOs: 1-260.
- integrated systems optionally include, one or more instruction set for selecting, aligning, translating, reverse- translating or viewing any one or more character strings corresponding to SEQ ID NOs:l- 260, with each other and/or with any additional nucleic acid or amino acid sequence.
- Figure 2 A-C Sequence diagrams illustrating putative motifs.
- subtilisins are commercially important serine endo-proteases whose broad specificity for peptide bonds and relative ease of production makes them highly valued for a range of applications including food and leather processing and as additives to laundry detergents for stain hydrolysis and solubilization. Because of their high value, subtilisins have been extensively studied, with over 100 crystal structures solved (Siezen et al. (1991) Protein Eng 4:719). The present invention provides novel subtilisin homologues with improved properties as well as combinations of properties. Among these properties are enhanced thermostability in high or low temperatures, stability and activity at high and low pH, and stability in organic solvents.
- a "polynucleotide sequence” is a nucleic acid, e.g., DNA, RNA (which is a polymer of nucleotides (A,C,T,U,G, etc. or naturally occurring or artificial nucleotide analogues) or a character string representing a nucleic acid, depending on context. Either the given nucleic acid or the complementary nucleic acid can be determined from any specified polynucleotide sequence.
- amino acid sequence is a polymer of amino acids (a protein, polypeptide, etc.) or a character string representing an amino acid polymer, depending on context.
- a nucleic acid, protein or other component is “isolated” when it is partially or completely separated from components with which it is normally associated (other proteins, nucleic acids, cells, synthetic reagents, etc.).
- a nucleic acid or polypeptide is "recombinant” when it is artificial or engineered, or derived from an artificial or engineered protein or nucleic acid.
- a "subsequence” or “fragment” is any portion of an entire sequence, up to and including the complete sequence.
- a vector is a composition for facilitating cell transduction by a selected nucleic acid, and/or expression of the nucleic acid in the cell.
- Vectors include, e.g., plasmids, cosmids, viruses, YACs, bacteria, poly-lysine, chromosome integration vectors, episomal vectors, etc.
- substantially an entire length of a polynucleotide or amino acid sequence refers to at least 70%, generally at least 80%, or typically 90% or more of a sequence.
- an “antibody” refers to a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes.
- the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- a typical immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light” (about 25 kD) and one "heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- VL variable light chain
- NH variable heavy chain
- Antibodies exist as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases.
- pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond.
- the F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab')2 dimer into an Fab' monomer.
- the Fab' monomer is essentially an Fab with part of the hinge region (see, Fundamental Immunolo y. 4 th Edition,W.E. Paul (ed.), Raven
- antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized de novo either chemically or by utilizing recombinant D ⁇ A methodology.
- the term antibody as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized de novo using recombinant D ⁇ A methodologies.
- Antibodies include single chain antibodies, including single chain Fv (sFv) antibodies in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide. A variety of additional terms are defined or otherwise characterized herein.
- sFv single chain Fv
- the invention provides isolated or recombinant subtilisin homologue polypeptides, and isolated or recombinant polynucleotides encoding the polypeptides. For convenience, comparisons are made to the subtilisin Savinase® and/or the polynucleotide encoding it.
- the 380 amino acid Savinase® polypeptide consists of an
- Polynucleotides encoding the polypeptides of the invention were discovered in libraries of subtilisin related sequences. DNA fragments were cloned into a Bacillus expression vector to generate a library of "diversified" region clones, corresponding to amino acids 55 through 227 of the mature protein (as indicated in Fig. 1 in bold). Library members were screened for protease activity, and assayed for a variety of desirable characteristics, including thermal stability, alkaline stability and activity in organic solvents.
- small libraries e.g., of 654 active clones in one exemplary trial, were tested for four properties: activity at 23°C, thermostability, solvent stability, and pH dependence.
- activity at 23°C e.g., thermostability
- solvent stability e.g., thermostability
- pH dependence e.g., thermostability, solvent stability, and pH dependence.
- To characterize the library colonies were grown on casein plates and protease activity was evaluated by the production of clearing halos. Active colonies were grown to stationary phase in LB medium, and the secreted protease was recovered from the medium and diluted 100-200 fold for assay procedures. The protease samples were assayed under five different conditions: pHIO; pH5.5, pH7.5; pH7.5 with 35% DMF; and pHIO following heat treatment.
- nucleic acids encoding proteases with up to three times more residual activity after heat treatment or up to 50% greater residual activity in 35% dimethylformamide (DMF) were obtained.
- many clones that produced proteases that were both more heat-stable and more active in organic solvent than Savinase® were also obtained. It will be appreciated that in addition to the properties described above, desirable properties such as psychrophilic activity (i.e., activity at low temperature), activity in the presence of compounds such as hypochlorite, supercritical carbon dioxide, etc., can be isolated from the present library.
- the present invention provides polynucleotide sequences encoding and polypeptide sequences corresponding to subtilisin homologues with one or more desirable properties such as increased thermotolerance, increased activity at ambient temperature, increased activity at alkaline pH, increased activity at acid pH, increased activity at neutral pH, increased activity in the presence of organic solvents, and the like, relative to Savinase®.
- the improved property is a conditional activity, or conditional property. For example, properties that facilitate large scale preparation and/or purification often can be described as conditional activities.
- Subtilisin homologues with high activity at, e.g., pH 10 relative to pH 7, or with high activity at pH 7 relative to pHIO can be purified at the inactive pH, and then provided in compositions, e.g., detergents, cleaning fluids, with a pH permissive of the high activity, reducing autoproteolysis in the preparation process.
- compositions e.g., detergents, cleaning fluids
- subtilisin homologues as well as subtilisin homologues activated by, e.g., reduced ionic strength (as by dilution of a composition of high ionic strength containing a subtilisin homologue) or by binding of a ligand, e.g., a component of a detergent, cleaning solution or cosmetic, can be isolated from among the sequences described herein, or derived therefrom according to the methods described herein.
- Exemplary recombinant, e.g., shuffled, nucleic acids which encode the diversified region of subtilisin homologue polypeptides having desirable properties or combinations of properties, or which can be screened to provide additional subtilisin homologues with these or other desirable properties, are provided in SEQ ID NO:l to SEQ ID NO: 130, which encode the diversified region polypeptides identified herein as SEQ ID NO: 131 to SEQ ID NO:260.
- the diversified regions indicated in the sequence listings are expressed in the context of a mature subtilisin or pre-pro peptide.
- SEQ ID NO: 131 to SEQ ID NO:260 correspond to amino acids 55 -227, inclusive.
- Polynucleotides and oligonucleotides of the invention can be prepared by standard solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined (e.g., by enzymatic or chemical ligation methods, or polymerase mediated recombination methods) to form essentially any desired continuous sequence.
- the polynucleotides and oligonucleotides of the invention can be prepared by chemical synthesis using, e.g., the classical phosphoramidite method described by Beaucage et al. (1981) Tetrahedron Letters 22:1859-69. or the method described by Matthes et al. (1984) EMBO J.
- oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.
- essentially any nucleic acid can be custom ordered from any of a variety of commercial sources, such as The Midland Certified Reagent Company (mcrc@oligos.com), The Great American Gene Company (http://www.genco.com), ExpressGen Inc. (www.expressgen.com), Operon Technologies Inc. (Alameda, CA) and many others.
- peptides and antibodies can be custom ordered from any of a variety of sources, such as PeptidoGenic (pkim@ccnet.com), HTI Bio-products, inc. (http://www.htibio.com), BMA Biomedicals Ltd (U.K.), Bio.Synthesis, Inc., and many others.
- Certain polynucleotides of the invention may also be obtained by screening cDNA libraries (e.g., libraries generated by recombining homologous nucleic acids as in typical shuffling methods) using oligonucleotide probes which can hybridize to or PCR-amplify polynucleotides which encode the subtilisin homologue polypeptides and fragments of those polypeptides.
- cDNA libraries e.g., libraries generated by recombining homologous nucleic acids as in typical shuffling methods
- oligonucleotide probes which can hybridize to or PCR-amplify polynucleotides which encode the subtilisin homologue polypeptides and fragments of those polypeptides.
- Procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook et al. (1989) infra, and Ausubel FM et al. (1989; supplemented
- polynucleotides of the invention can be obtained by altering a naturally occurring backbone, e.g., by mutagensis or oligonucleotide shuffling. In other cases, such polynucleotides can be made by in silico or oligonucleotide shuffling methods as described in the references cited below.
- the polynucleotides of the invention include sequences which encode novel mature subtilisin homologues and sequences complementary to the coding sequences, and novel fragments of coding sequence and complements thereof.
- the polynucleotides can be in the form of RNA or in the form of DNA, and include mRNA, cRNA, synthetic RNA and DNA, and cDNA.
- the polynucleotides can be double-stranded or single-stranded, and if single-stranded, can be the coding strand or the non-coding (anti-sense, complementary) strand.
- the polynucleotides optionally include the coding sequence of a subtilisin homologue (i) in isolation, (ii) in combination with additional coding sequence, so as to encode, e.g., a fusion protein, a pre-protein, a prepro-protein, or the like, (iii) in combination with non- coding, sequences, such as introns, control elements such as a promoter, a terminator element, or 5' and/or 3' untranslated regions effective for expression of the coding sequence in a suitable host, and/or (iv) in a vector or host environment in which the subtilisin homologue coding sequence is a heterologous gene. Sequences can also be found in combination with typical compositional formulations of nucleic acids, including in the presence of carriers
- the polynucleotides of the invention have a variety of uses in, for example: recombinant production (i.e., expression) of the subtilisin homologue polypeptides of the invention; as detergent components; in food processing; as immunogens; as diagnostic probes for the presence of complementary or partially complementary nucleic acids (including for detection of natural subtilisin coding nucleic acids; as substrates for further diversity generation, e.g., diversity generating reactions, such as shuffling reactions or mutation reactions, to produce new and/or improved subtilisin homologues, and the like.
- subtilisin homologue polypeptides or, simply, “subtilisin homologues” are used in recombinant DNA molecules that direct the expression of the subtilisin homologue polypeptides in appropriate host cells, such as bacterial cells. Due to the inherent degeneracy of the genetic code, other nucleic acid sequences which encode substantially the same or a functionally equivalent amino acid sequence are also used to clone and express the subtilisin homologues.
- Modified Coding Sequences As will be understood by those of skill in the art, it can be advantageous to modify a coding sequence to enhance its expression in a particular host.
- the genetic code is redundant with 64 possible codons, but most organisms preferentially use a subset of these codons.
- the codons that are utilized most often in a species are called optimal codons, and those not utilized very often are classified as rare or low-usage codons (see, e.g., Zhang SP et al. (1991) Gene 105:61-72 ⁇ Codons can be substituted to reflect the preferred codon usage of the host, a process sometimes called "codon optimization" or "controlling for species codon bias.”
- Optimized coding sequence containing codons preferred by a particular prokaryotic or eukaryotic host can be prepared, for example, to increase the rate of translation or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, as compared with transcripts produced from a non-optimized sequence.
- Translation stop codons can also be modified to reflect host preference. For example, preferred stop codons for S. cerevisiae and mammals are UAA and UGA respectively. The preferred stop codon for monocotyledonous plants is UGA, whereas insects and E. coli prefer to use UAA as the stop codon (Dalphin ME et al. (1996) Nuc. Acids Res. 24: 216-218).
- polynucleotide sequences of the present invention can be engineered in order to alter a subtilisin homologue coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product.
- alterations may be introduced using techniques that are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, alter glycosylation patterns, change codon preference, introduce splice sites, etc.
- the present invention also includes recombinant constructs comprising one or more of the nucleic acid sequences as broadly described above.
- the constructs comprise a vector, such as, a plasmid, a cosmid, a phage, a virus, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), or the like, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation.
- the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- NASBA RNA polymerase mediated techniques
- the present invention also relates to engineered host cells that are transduced (transformed or transfected) with a vector of the invention (e.g., an invention cloning vector or an invention expression vector), as well as the production of polypeptides of the invention by recombinant techniques.
- a vector of the invention e.g., an invention cloning vector or an invention expression vector
- the vector may be, for example, a plasmid, a viral particle, a phage, etc., or a non-replicating vector, such as liposomes, naked or conjugated DNA, DNA-microparticles, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants, or amplifying the subtilisin homologue gene.
- Culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, e.g., Sambrook, Ausubel and Berger, as well as e.g., Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein.
- Subtilisin homologue proteins of the invention can be produced in non- animal cells such as plants, yeast, fungi, bacteria and the like.
- non-animal cell culture can be found in Payne et al. (1992) Plant Cell and Tissue Culture in Liquid Systems John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds) (1995) Plant Cell Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer- Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, FL.
- Polynucleotides of the present invention can be incorporated into any one of a variety of expression vectors suitable for expressing a polypeptide.
- Suitable vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others.
- any vector that transduces genetic material into a cell, and, if replication is desired, which is replicable and viable in the relevant host can be used.
- the invention polynucleotide is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis.
- transcription control sequences include: LTR or S V40 promoter, E. coli lac or trp promoter, phage lambda P L promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses.
- This invention expression vector optionally contains a ribosome binding site for translation initiation, and a transcription terminator.
- the vector also optionally includes appropriate sequences for amplifying expression, e.g., an enhancer.
- the expression vectors of the present invention optionally contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
- Vectors of the present invention can be employed to transform an appropriate host to permit the host to express an invention protein or polypeptide.
- appropriate expression hosts include: bacterial cells, such as E. coli, B. subtilis, Streptomyces, and Salmonella typhimurium; fungal cells, such as Saccharomyces cerevisiae, Pichia pastoris, and Neurospora crassa; insect cells such as Drosophila and Spodopterafrugiperda; mammalian cells such as CHO, COS, BHK, HEK 293 or Bowes melanoma; plant cells, etc. It is understood that not all cells or cell lines need to be capable of producing fully functional subtilisin homologues; for example, antigenic fragments of an subtilisin homologue may be produced.
- the invention is not limited by the host cells employed.
- a number of expression vectors may be selected depending upon the use intended for the subtilisin homologue. For example, when large quantities of subtilisin homologue or fragments thereof are needed for commercial production or for induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be desirable. Such vectors include, but are not limited to, multifunctional E.
- subtilisin homologue coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; pDSf vectors (Van Heeke & Schuster (1989) J Biol Chem 264:5503-5509); pET vectors (Novagen, Madison WI); and the like.
- subtilisin homologue polypeptides of the invention may be used for production of the subtilisin homologue polypeptides of the invention.
- constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH.
- a variety of expression systems including viral- based systems, may be utilized.
- a coding sequence e.g., of a subtilisin homologue polypeptide
- an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion of a subtilisin polypeptide coding region into a nonessential El or E3 region of the viral genome will result in a viable virus capable of expressing subtilisin homologue in infected host cells (Logan and Shenk (1984 Proc Natl Acad Sci USA 81:3655-3659).
- transcription enhancers such as the rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.
- RSV rous sarcoma virus
- Specific initiation signals can aid in efficient translation of a subtilisin homologue coding sequence of the present invention. These signals can include, e.g., the ATG initiation codon and adjacent sequences. In cases where a subtilisin homologue coding sequence, its initiation codon and upstream sequences are inserted into an appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence (e.g., a mature protein coding sequence), or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic.
- Enhancers appropriate to the cell system in use (Scharf et al. (1994) Results Probl Cell Differ 20:125-62; Bittner et al. (1987) Methods in Enzvmol. 153:516-544).
- Polynucleotides of the invention can also be fused, for example, in-frame to nucleic acids encoding a secretion/localization sequence, to target polypeptide expression to a desired cellular compartment, membrane, or organelle of a mammalian cell, or to direct polypeptide secretion to the periplasmic space or into the cell culture media.
- sequences are known to those of skill, and include secretion leader peptides, organelle targeting sequences (e.g., nuclear localization sequences, ER retention signals, mitochondrial transit sequences, chloroplast transit sequences), membrane localization/anchor sequences (e.g., stop transfer sequences, GPI anchor sequences), and the like.
- the present invention relates to host cells containing the above-described constructs.
- the host cell can be a eukaryotic cell, such as a mammalian cell, a yeast cell, or a plant cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, electroporation, or other common techniques (Davis et al. (1986) Basic Methods in Molecular Biology).
- a host cell strain is optionally chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion.
- Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.
- Post-translational processing which cleaves a "pre” or a "prepro” form of the protein may also be important for correct insertion, folding and/or function.
- Different host cells such as E. coli, Bacillus sp., yeast or mammalian cells such as CHO, HeLa, BHK, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms, e.g., for post-translational activities and may be chosen to ensure the desired modification and processing of the introduced, foreign protein.
- stable expression systems For long-term, high-yield production of recombinant proteins, stable expression systems can be used.
- cell lines which stably express a polypeptide of the invention are transduced using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene.
- cells may be allowed to grow for a period determined to be appropriate for the cell type, e.g., 1-2 days for mammalian cell, 1 or more hours for bacterial cells, in an enriched media before they are switched to selective media.
- the purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences.
- resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.
- Host cells transformed with a nucleotide sequence encoding a polypeptide of the invention are optionally cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture.
- the protein or fragment thereof produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly, depending on the sequence and/or the vector used.
- expression vectors containing polynucleotides encoding mature subtilisin homologues of the invention can be designed with signal sequences which direct secretion of the mature polypeptides through a prokaryotic or eukaryotic cell membrane.
- Polynucleotides of the present invention may also comprise a coding sequence fused in-frame to a marker sequence which, e.g., facilitates purification of the encoded polypeptide.
- purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, a sequence which binds glutathione (e.g., GST), a hemagglutinin (HA) tag (corresponding to an epitope derived from the influenza hemagglutinin protein; Wilson et al.
- One expression vector contemplated for use in the compositions and methods described herein provides for expression of a fusion protein comprising a polypeptide of the invention fused to a polyhistidine region separated by an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography, as described in Porath et al.
- pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
- GST glutathione S-transferase
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.
- the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
- Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
- Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.
- Polypeptides of the invention can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography (e.g., using any of the tagging systems noted herein), hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as desired, in completing the configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed in the final purification steps.
- HPLC high performance liquid chromatography
- subtilisin homologues of the invention in some cases it is desirable to produce the subtilisin homologues of the invention in a large scale suitable for industrial and/or commercial applications. In such cases bulk fermentation procedures are employed. Briefly, polynucleotides comprising any one of SEQ ID NO:l to SEQ ID NO: 130, or other nucleic acids encoding subtilisin homologues of the invention can be cloned into an expression vector.
- U.S. Patent No. 5,955,310 to Widner et al. “METHODS FOR PRODUCING A POLYPEPTIDE IN A BACILLUS CELL,” describes a vector with tandem promoters, and stabilizing sequences operably linked to a polypeptide encoding sequence.
- the vector After inserting the polynucleotide of interest into a vector, the vector is transformed into a bacterial, e.g., a Bacillus subtilis strain PL1801IIE (amyE, apr, npr, spoIIE::Tn917) host.
- a Bacillus subtilis strain PL1801IIE (amyE, apr, npr, spoIIE::Tn917) host.
- an expression vector into a Bacillus cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen (1979) Molecular General Genetics 168:111), by using competent cells (see, e.g., Young and Spizizin (1961) Journal of Bacteriology 81 : 823 , or Dubnau and Davidoff- Abelson ( 1971 ) Journal of Molecular Biology 56:209), by electroporation (see, e.g., Shigekawa and Dower (1988) Biotechniques 6:742), or by conjugation (see, e.g., Koehler and Thome (1987) Journal of Bacteriology 169:5271), also Ausubel, Sambrook and Berger, all supra.
- the transformed cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods that are known in the art.
- the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated.
- the cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection).
- the secreted polypeptide can be recovered directly from the medium.
- the resulting polypeptide may be isolated by methods known in the art.
- the polypeptide may be isolated from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray- drying, evaporation, or precipitation.
- the isolated polypeptide may then be further purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Bollag et al. (1996) Protein Methods. 2 nd Edition Wiley-Liss, NY; Walker (1996) The Protein
- Cell-free transcription/translation systems can also be employed to produce polypeptides using DNAs or RNAs of the present invention. Several such systems are commercially available. A general guide to in vitro transcription and translation protocols is found in Tyrnms (1995) In vitro Transcription and Translation Protocols: Methods in Molecular Biology Volume 37, Garland Publishing, NY.
- Polypeptides of the invention may contain one or more modified amino acid.
- the presence of modified amino acids may be advantageous in, for example, (a) increasing polypeptide serum half -life, (b) reducing polypeptide antigenicity, (c) increasing polypeptide storage stability.
- Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N-X-S/T motifs during expression in mammalian cells) or modified by synthetic means.
- Non-limiting examples of a modified amino acid include a glycosylated amino acid, a sulfated amino acid, a prenlyated (e.g., farnesylated, geranylgeranylated) amino acid, an acetylated amino acid, an acylated amino acid, a PEG-ylated amino acid, a biotinylated amino acid, a carboxylated amino acid, a phosphorylated amino acid, and the like.
- polynucleotides also referred to herein as oligonucleotides, typically having at least 12 bases, preferably at least 15, more preferably at least 20, 30, or 50 or more bases, which hybridize under highly stringent conditions to an subtilisin homologue polynucleotide sequence described above.
- the polynucleotides may be used as probes, primers, sense and antisense agents, and the like, according to methods as noted supra.
- subtilisin homologue polypeptides of the invention may be produced, some of which bear substantial identity to the nucleic acid sequences explicitly disclosed herein.
- codon table 1 For instance, inspection of the codon table (Table 1) shows that codons AGA, AGG, CGA, CGC, CGG, and CGU all encode the amino acid arginine.
- the codon can be altered to any of the corresponding codons described above without altering the encoded polypeptide. It is understood that U in an RNA sequence corresponds to T in a DNA sequence.
- a silent variation of this sequence includes AGT ACC CAG GAC GGA, both sequences which encode the amino acid sequence STQDG, corresponding to amino acids 1-5 of SEQ ID NO: 131.
- Such "silent variations” are one species of “conservatively modified variations", discussed below.
- each codon in a nucleic acid can be modified by standard techniques to encode a functionally identical polypeptide. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in any described sequence.
- the invention provides each and every possible variation of nucleic acid sequence encoding a polypeptide of the invention that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code (e.g., as set forth in Table 1) as applied to the nucleic acid sequence encoding an subtilisin homologue polypeptide of the invention. All such variations of every nucleic acid herein are specifically provided and described by consideration of the sequence in combination with the genetic code. Any variant can be produced as noted herein.
- Constants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or, where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences.
- One of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than about
- “conservatively substituted variations" of a listed polypeptide sequence of the present invention include substitutions of a small percentage, typically less than about 5%, more typically less than about 2% and often less than about 1%, of the amino acids of the polypeptide sequence, with a conservatively selected amino acid of the same conservative substitution group.
- a conservatively substituted variation of the polypeptide identified herein as SEQ ID NO: 131 will contain "conservative substitutions", according to the six groups defined above, in up to 8 residues (i.e., about 5% of the amino acids) in the 169 amino acid polypeptide.
- AAL NNS IGV L examples of conservatively substituted variations of this region, include: AAL QNA LGV V and
- sequences which do not alter the encoded activity of a nucleic acid molecule is a conservative variation of the basic nucleic acid.
- sequences which do not alter the encoded activity of a nucleic acid molecule is a conservative variation of the basic nucleic acid.
- conservative variations of the nucleic acid constructs which are disclosed yield a functionally identical construct.
- "silent substitutions" i.e., substitutions in a nucleic acid sequence which do not result in an alteration in an encoded polypeptide
- substitutions are an implied feature of every nucleic acid sequence which encodes an amino acid.
- Non-conservative modifications of a particular nucleic acid are those which substitute any amino acid not characterized as a conservative substitution.
- These include substitutions of basic or acidic amino acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gin for Val, He, Leu or Met), aromatic amino acid for basic or acidic amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gin) or any other substitution not replacing an amino acid with a like amino acid.
- polypeptides and nucleic acids employed in the subject invention need not be identical, but can be substantially identical (or substantially similar), to the corresponding sequence of a subtilisin homologue molecule or related molecule.
- the polypeptides (and peptides) can be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use.
- the polypeptides of the invention can be modified in a number of ways so long as they comprise a sequence substantially similar or substantially identical (as defined below) to a sequence in a subtilisin homologue molecule. Alignment and comparison of relatively short amino acid sequences (less than about 30 residues) is typically straightforward.
- Optimal alignment of sequences for aligning a comparison window can be conducted by the local homology algorithm of Smith and Waterman (1981) Adv Appl Math 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J Mol Biol 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc Natl Acad Sci USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI; and BLAST, see, e.g., Altschul et al., (1977) Nuc Acids Res 25:3389-3402 and Altschul et al., (1990) J Mol Biol 215:403-410), or by inspection, with the best alignment (i.e., resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods being
- sequence identity means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over a window of comparison.
- percentage of sequence identity or “percentage bf sequence similarity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical residues occur in both nucleotide sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity (or percentage of sequence similarity).
- sequence identity likewise means that two polypeptide sequences are identical (on an amino acid-by-amino acid basis) over a window of comparison, and a percentage of amino acid residue sequence identity (or percentage of amino acid residue sequence similarity), also can be calculated. Maximum correspondence can be determined by using one of the sequence algorithms described herein (or other algorithms available to those of ordinary skill in the art) or by visual inspection.
- substantial identity or substantial similarity means that two peptide sequences, when optimally aligned, such as by the programs BLAST, GAP or BESTFIT using default gap weights (described in detail below) or by visual inspection, share at least about 60 percent, 70 percent, or 80 percent sequence identity or sequence similarity, preferably at least about 90 percent amino acid residue sequence identity or sequence similarity, more preferably at least about 95 percent sequence identity or sequence similarity, or more (including, e.g., about 96, 97, 98, 98.5, 99, 99.5 or more percent amino acid residue sequence identity or sequence similarity).
- the term substantial identity or substantial similarity means that the two nucleic acid sequences, when optimally aligned, such as by the programs BLAST, GAP or BESTFIT using default gap weights (described in detail below) or by visual inspection, share at least about 60 percent, 70 percent, or 80 percent sequence identity or sequence similarity, preferably at least about 90 percent amino acid residue sequence identity or sequence similarity, more preferably at least about 95 percent sequence identity or sequence similarity, or more (including, e.g., about 96, 97, 98, 98.5, 99, 99.5 or more percent nucleotide sequence identity or sequence similarity).
- the present invention provides subtilisin homologue nucleic acids having at least about 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 98.5%, 99%), 99.5% or more percent sequence identity or sequence similarity with the nucleic acid sequences of any of SEQ ID NOs: 1-130 or fragments thereof.
- the present invention provides subtilisin homologue polypeptides having at least about 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 98.5, 99%, 99.5% or more percent sequence identity or sequence similarity with the amino acid sequences of any of SEQ ID NOs: 131- 260, or fragments thereof that exhibit endo-protease activity.
- the present invention provides subtilisin homologue polypeptides that are substantially identical or substantially similar over at least about 20 (or about 30, 40, 60, 80, 100 or more) contiguous amino acids of at least one of SEQ ID NOs: 131-260; some such polypeptides may exhibit improved properties such as thermostability, activity at low or neutral pH, or activity in organic solvents, and the like.
- parameters are set such that one or more sequences of the invention are identified by alignment to a query sequence selected from among SEQ ID NO: 1 to SEQ ID NO: 130, while sequences corresponding to unrelated polypeptides, e.g., those encoded by nucleic acid sequence represented by GenBank accession numbers: M65086, D13157, S48754, AB005792, D29688, and M28537, are not identified.
- residue positions which are not identical differ by conservative amino acid substitutions.
- Conservative amino acid substitution refers to the interchangeability of residues having similar side chains.
- a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine
- a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine
- a group of amino acids having amide-containing side chains is asparagine and glutamine
- a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan
- a group of amino acids having basic side chains is lysine, arginine, and histidine
- a group of amino acids having sulfur-containing side chains is cysteine and methionine.
- Preferred conservative amino acids substitution groups are: valine-leucine- isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine- glutamine.
- a preferred example of an algorithm that is suitable for determining percent sequence identity or sequence similarity is the FASTA algorithm, which is described in Pearson, W.R. & Lipman, D. J., (1988) Proc Natl Acad Sci USA 85:2444. See also, W. R. Pearson, (1996) Methods Enzvmology 266:227-258.
- BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity or percent sequence similarity for the nucleic acids and polypeptides and proteins of the invention.
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http: //www.ncbi.nlm.nih.gov/).
- This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence.
- T is referred to as the neighborhood word score threshold (Altschul et al., supra).
- a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
- the stringency of comparison can be increased until the program identifies only sequences that are more closely related to those in the sequence listings herein (i.e., SEQ ID NO:l to SEQ ID NO:130 or, alternatively, SEQ ID NO:131 to SEQ ID NO:260), rather than sequences that are more closely related to other similar sequences such as, e.g., those nucleic acid sequences represented by GenBank accession numbers: M65086, D13157, S48754, AB005792, D29688, and M28537 or other similar molecules found in, e.g., GenBank .
- the stringency of comparison of the algorithms can be increased so that all known prior art (e.g., those represented by GenBank accession numbers: M65086, D13157, S48754, AB005792, D29688, and M28537 or other similar molecules found in, e.g., GenBank, as well as sequences represented by GenBank accession numbers: P29600, P41362, P29599, P27693, P20724, P41363, P00780, P00781, P35835, P00783, P29142, P04189, P07518, P00782, P04072, P16396, P29140, P29139, P08594, P16588, P11018, P54423, P40903, P23314, P23653, P33295, P42780, and P80146) is excluded.
- GenBank accession numbers e.g., those represented by GenBank accession numbers: M65086, D13157, S48754, AB005792, D29688, and M
- the BLAST algorithm also performs a statistical analysis of the similarity or identity between two sequences (see, e.g., Karlin & Altschul, (1993) Proc Natl Acad Sci USA 90:5873-5787).
- One measure of similarity or identity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
- PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity or percent sequence similarity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, (1987) J Mol Evol 35:351-360. The method used is similar to the method described by Higgins & Sharp, (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids.
- the multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments.
- the program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters.
- PILEUP a reference sequence is compared to other test sequences to determine the percent sequence identity (or percent sequence similarity) relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.
- PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux et al., (1984) Nuc Acids Res 12:387-395).
- CLUSTALW CLUSTALW program
- CLUSTALW performs multiple pairwise comparisons between groups of sequences and assembles them into a multiple alignment based on homology. Gap open and Gap extension penalties were 10 and 0.05 respectively.
- the BLOSUM algorithm can be used as a protein weight matrix (Henikoff and Henikoff, (1992) Proc Natl Acad Sci USA 89:10915-10919).
- Nucleic Acid Hybridization Nucleic acids "hybridize" when they associate, typically in solution.
- nucleic acids hybridize due to a variety of well characterized physico-chemical forces, such as hydrogen bonding, solvent exclusion, base stacking and the like. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory
- highly stringent hybridization and wash conditions are selected to be about 5° C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
- T m is the temperature (under defined ionic strength and pH) at which 50% of the test sequence hybridizes to a perfectly matched probe.
- Very stringent conditions are selected to be equal to the T m for a particular probe.
- An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42°C, with the hybridization being carried out overnight.
- stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (see, Sambrook, supra for a description of SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove background probe signal.
- An example low stringency wash is 2x SSC at 40°C for 15 minutes.
- a signal to noise ratio of 5x (or higher) than that observed for an unmatched probe (e.g., a publically available subtilisin coding nucleic acid with a sequence found in Genbank prior to the filing of the present application) in the particular hybridization assay indicates detection of a specific hybridization.
- Comparative hybridization can be used to identify nucleic acids of the invention, and this comparative hybridization method is a preferred method of distinguishing nucleic acids of the invention.
- detection of highly stringent hybridization in the context of the present invention indicates strong structural similarity to, e.g., the nucleic acids provided in the sequence listing herein.
- One measure of stringent hybridization is the ability to hybridize to one of the listed nucleic acids (e.g., nucleic acid sequences SEQ ID NO:l to SEQ ID NO: 130, and complementary polynucleotide sequences thereof, or a subsequence thereof, (e.g., subsequences encoding amino acid positions 71-95, 86-110, 111-135, and/or 196-230) under highly stringent conditions.
- Stringent hybridization and wash conditions can easily be determined empirically for any test nucleic acid.
- the hybridization and wash conditions are gradually increased (e.g., by increasing temperature, decreasing salt concentration, increasing detergent concentration and/or increasing the concentration of organic solvents such as formalin in the hybridization or wash), until a selected set of criteria are met.
- the hybridization and wash conditions are gradually increased until a probe comprising one or more nucleic acid sequences selected from SEQ ID NO:l to SEQ ID NO: 130, or complementary polynucleotide sequences thereof, binds to a perfectly matched complementary target (again, a nucleic acid comprising one or more nucleic acid sequences selected from SEQ ID NO:l to SEQ ID NO: 130, and complementary polynucleotide sequences thereof), with a signal to noise ratio that is at least 5x as high as that observed for hybridization of the probe to an unmatched target, and is sometimes lOx, 20x, 50x or even higher, depending on the desired discrimination.
- the unmatched target is a nucleic acid corresponding to a known subtilisin homologue, e.g., an subtilisin homologue nucleic acid (other than those in the accompanying sequence listing) that is present in a public database such as GenBankTM at the time of filing of the subject application.
- a known subtilisin homologue e.g., an subtilisin homologue nucleic acid (other than those in the accompanying sequence listing) that is present in a public database such as GenBankTM at the time of filing of the subject application.
- Examples of such unmatched target nucleic acids include, e.g., those with the following GenBank accession numbers: M65086, D13157, S48754, AB005792, D29688, and M28537. Additional such sequences can be identified in GenBank by one of skill.
- a test nucleic acid is said to specifically hybridize to a probe nucleic acid when it hybridizes at least V ⁇ as well to the probe as to the perfectly matched complementary target, i.e., with a signal to noise ratio at least Vi as high as hybridization of the probe to the target under conditions in which the perfectly matched probe binds to the perfectly matched complementary target with a signal to noise ratio that is at least about 5x-10x, and occasionally 20x, 50x or greater than that observed for hybridization to any of the unmatched target nucleic acids M65086, D13157, S48754, AB005792, D29688, and M28537.
- Ultra high-stringency hybridization and wash conditions are those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least lOx, sometimes 20x, and occasionally 50x as high as that observed for hybridization to any of the unmatched target nucleic acids M65086, D13157, S48754, AB005792, D29688, and M28537.
- a target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least l that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-high stringency conditions.
- even higher levels of stringency can be determined by gradually increasing the hybridization and/or wash conditions of the relevant hybridization assay. For example, those in which the stringency of hybridization and wash conditions are increased until the signal to noise ratio for binding of the probe to the perfectly matched complementary target nucleic acid is at least lOx, 20X, 50X, 100X, or 500X or more as high as that observed for hybridization to any of the unmatched target nucleic acids M65086, D13157, S48754, AB005792, D29688, and M28537can be identified.
- a target nucleic acid which hybridizes to a probe under such conditions, with a signal to noise ratio of at least Y ⁇ that of the perfectly matched complementary target nucleic acid is said to bind to the probe under ultra-ultra-high stringency conditions.
- the most similar sequences selected from among those available in GenBank, as of the filing date can be used as the control sequences.
- Target nucleic acids which hybridize to the nucleic acids represented by SEQ ID NO: 1 to SEQ ID NO: 130, under high, ultra-high and ultra-ultra high stringency conditions are a feature of the invention.
- nucleic acids include those with one or a few silent or conservative nucleic acid substitutions as compared to a given nucleic acid sequence.
- Nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code, or when antisera generated against one or more of SEQ ID NO: 131 to SEQ ID NO:260 which has been subtracted using the polypeptides encoded by the following subtilisin sequences in GenBank: M65086, D13157, S48754, AB005792, D29688, and M28537. Further details on immunological identification of polypeptides of the invention are found below.
- the invention provides a nucleic acid which comprises a unique subsequence in a nucleic acid selected from SEQ ID NO:l to SEQ ID NO: 130.
- the unique subsequence is unique as compared to a nucleic acid corresponding to any of: M65086, D13157, S48754, AB005792, D29688, and M28537.
- Such unique subsequences can be determined by aligning any of SEQ ID NO:l to SEQ ID NO: 130 against the complete set of nucleic acids corresponding to M65086, D13157, S48754, AB005792, D29688, and M28537. Alignment can be performed using the BLAST algorithm set to default parameters. Any unique subsequence is useful, e.g., as a probe to identify the nucleic acids of the invention.
- the invention includes a polypeptide which comprises a unique subsequence in a polypeptide selected from: SEQ ID NO: 131 to SEQ ID NO:260.
- the unique subsequence is unique as compared to a polypeptide corresponding to any of (GenBank accession numbers): P29600, P41362, P29599, P27693, P20724, P41363, P00780, P00781, P35835, P00783, P29142, P04189, P07518, P00782, P04072, P16396, P29140, P29139, P08594, P16588, PI 1018, P54423, P40903, P23314, P23653, P33295, P42780, and P80146.
- the polypeptide is aligned against the complete set of polypeptides corresponding to P29600, P41362, P29599, P27693, P20724, P41363,
- the invention also provides for target nucleic acids which hybridizes under stringent conditions to a unique coding oligonucleotide which encodes a unique subsequence in a polypeptide selected from: SEQ ID NO: 131 to SEQ ID NO:260, wherein the unique subsequence is unique as compared to a polypeptide corresponding to any of the control polypeptides. Unique sequences are determined as noted above.
- the stringent conditions are selected such that a perfectly complementary oligonucleotide to the coding oligonucleotide hybridizes to the coding oligonucleotide with at least about a 5-1 Ox higher signal to noise ratio than for hybridization of the perfectly complementary oligonucleotide to a control nucleic acid corresponding to any of the control polypeptides.
- Conditions can be selected such that higher ratios of signal to noise are observed in the particular assay which is used, e.g., about 15x, 20x, 30x, 50x or more.
- the target nucleic acid hybridizes to the unique coding oligonucleotide with at least a 2x higher signal to noise ratio as compared to hybridization of the control nucleic acid to the coding oligonucleotide.
- higher signal to noise ratios can be selected, e.g., about 5x, lOx, 20x, 30x, 50x or more.
- the particular signal will depend on the label used in the relevant assay, e.g., a fluorescent label, a colorimetric label, a radio active label, or the like.
- the polynucleotides of the invention are optionally used as substrates for a variety of diversity generating procedures, including recombination and recursive recombination (e.g., DNA shuffling) reactions, i.e., to produce additional subtilisin homologues with desired properties.
- recombination and recursive recombination e.g., DNA shuffling
- additional subtilisin homologues i.e., to produce additional subtilisin homologues with desired properties.
- recombination and recursive recombination e.g., DNA shuffling
- a variety of diversity generating protocols are available and described in the art.
- the procedures can be used separately, and/or in combination to produce one or more variants of a nucleic acid or set of nucleic acids, as well variants of encoded proteins.
- nucleic acid libraries include, e.g., nucleic acid libraries
- any of the diversity generating procedures described herein can be the generation of one or more nucleic acids, which can be selected or screened for nucleic acids with or which confer desirable properties, or that encode proteins with or which confer desirable properties.
- any nucleic acids that are produced can be selected for a desired activity or property, e.g. subtilisin homologues with improved thermostability, increased activity at neutral or low pH, increased activity in organic solvents, and the like. This can include identifying any activity that can be detected, for example, in an automated or automatable format, by any of the assays in the art, including the various methods for assessing protease activity described herein, and known in the art. A variety of related (or even unrelated) properties can be evaluated, in serial or in parallel, at the discretion of the practitioner.
- Mutational methods of generating diversity include, for example, site- directed mutagenesis (Ling et al. (1997) "Approaches to DNA mutagenesis: an overview” Anal Biochem. 254(2): 157-178; Dale et al. (1996) "Oligonucleotide-directed random mutagenesis using the phosphorothioate method” Methods Mol. Biol. 57:369-374; Smith
- sequence modification methods such as mutation, recombination, etc.
- any of the methods cited above can be adapted to the present invention to evolve the subtilisin homologues discussed herein to produce new endo-proteases with improved properties. Both the methods of making such subtilisins and the subtilisins produced by these methods are a feature of the invention.
- Nucleic acids can be recombined in vitro by any of a variety of techniques discussed in the references above, including e.g., DNAse digestion of nucleic acids to be recombined followed by ligation and/or PCR reassembly of the nucleic acids.
- sexual PCR mutagenesis can be used in which random (or pseudo random, or even non-random) fragmentation of the DNA molecule is followed by recombination, based on sequence similarity, between DNA molecules with different but related DNA sequences, in vitro, followed by fixation of the crossover by extension in a polymerase chain reaction.
- This process and many process variants is described in several of the references above, e.g., in Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751.
- any of the subtilisin homologue nucleic acids described herein can be recombined in vitro to generate additional subtilisin homologues with desired properties.
- nucleic acids can be recursively recombined in vivo, e.g., by allowing recombination to occur between nucleic acids in cells.
- Many such in vivo recombination formats are set forth in the references noted above. Such formats optionally provide direct recombination between nucleic acids of interest, or provide recombination between vectors, viruses, plasmids, etc., comprising the nucleic acids of interest, as well as other formats. Details regarding such procedures are found in the references noted above. Accordingle, any of the subtilisin homologue encoding nucleic acids can be recombined in vivo to produce novel subtilisin homologues with desired properties.
- Whole genome recombination methods can also be used in which whole genomes of cells or other organisms are recombined, optionally including spiking of the genomic recombination mixtures with desired library components (e.g., genes corresponding to the pathways of the present invention). These methods have many applications, including those in which the identity of a target gene is not known. Details on such methods are found, e.g., in WO 98/31837 by del Cardayre et al.
- subtilisin homologue nucleic acids of the invention can, thus, be recombined using whole genome recombination methods to generate additional subtilisin homologues with advantageous characteristics.
- Synthetic recombination methods can also be used, in which oligonucleotides corresponding to targets of interest, e.g., the subtilisin homologues provided herein, are synthesized and reassembled in PCR or ligation reactions which include, for example, oligonucleotides which correspond to more than one parental nucleic acid, oligonucleotides corresponding to consensus sequences for a plurality of parental nucleic acids, (optionally incorporating one or more variable nucleotide positions), oligonucleotides incorporating proven or putative functional motifs, etc., thereby generating new recombined nucleic acids.
- targets of interest e.g., the subtilisin homologues provided herein
- Oligonucleotides can be made by standard nucleotide addition methods, or can be made, e.g., by tri-nucleotide synthetic approaches. Details regarding such approaches are found in the references noted above, including, e.g., WO 00/42561 by Crameri et al., "Olgonucleotide Mediated Nucleic Acid Recombination;” PCT/US00/26708 by Welch et al, "Use of Codon- Varied Oligonucleotide Synthesis for Synthetic Shuffling;” WO 00/42560 by Selifonov et al, “Methods for Making Character Strings, Polynucleotides and Polypeptides Having Desired Characteristics;” and WO 00/42559 by Selifonov and Stemmer “Methods of Populating Data Structures for Use in Evolutionary Simulations.”
- silico methods of recombination can be effected in which genetic algorithms are used in a computer to recombine sequence strings which correspond to homologous (or even non-homologous) nucleic acids.
- the resulting recombined sequence strings are optionally converted into nucleic acids by synthesis of nucleic acids which correspond to the recombined sequences, e.g., in concert with oligonucleotide synthesis/ gene reassembly techniques. This approach can generate random, partially random or designed variants.
- This methodology is generally applicable to the present invention in providing for recombination of subtilisin homologues in silico and/ or the generation of corresponding nucleic acids or proteins.
- Many methods of accessing natural diversity e.g., by hybridization of diverse nucleic acids or nucleic acid fragments to single-stranded templates, followed by polymerization and/or ligation to regenerate full-length sequences, optionally followed by degradation of the templates and recovery of the resulting modified nucleic acids can be similarly used.
- the fragment population derived from the genomic library(ies) is annealed with partial, or, often approximately full length ssDNA or RNA corresponding to the opposite strand.
- the parental polynucleotide strand can be removed by digestion (e.g., if RNA or uracil-containing), magnetic separation under denaturing conditions (if labeled in a manner conducive to such separation) and other available separation/purification methods.
- the parental strand is optionally co-purified with the chimeric strands and removed during subsequent screening and processing steps.
- single-stranded molecules are converted to double- stranded DNA (dsDNA) and the dsDNA molecules are bound to a solid support by ligand-mediated binding. After separation of unbound DNA, the selected DNA molecules are released from the support and introduced into a suitable host cell to generate a library enriched sequences which hybridize to the probe.
- dsDNA double- stranded DNA
- a library produced in this manner provides a desirable substrate for further diversification using any of the procedures described herein.
- Any of the preceding general recombination formats can be practiced in a reiterative fashion (e.g., one or more cycles of mutation/recombination or other diversity generation methods, optionally followed by one or more selection methods) to generate a more diverse set of recombinant nucleic acids.
- Mutagenesis employing polynucleotide chain termination methods have also been proposed (see e.g., U.S. Patent No. 5,965,408, "Method of DNA reassembly by interrupting synthesis" to Short, and the references above), and can be applied to the present invention.
- double stranded DNAs corresponding to one or more genes sharing regions of sequence similarity are combined and denatured, in the presence or absence of primers specific for the gene.
- the single stranded polynucleotides are then annealed and incubated in the presence of a polymerase and a chain terminating reagent (e.g., ultraviolet, gamma or X-ray irradiation; ethidium bromide or other intercalators; DNA binding proteins, such as single strand binding proteins, transcription activating factors, or histones; polycyclic aromatic hydrocarbons; trivalent chromium or a trivalent chromium salt; or abbreviated polymerization mediated by rapid thermocycling; and the like), resulting in the production of partial duplex molecules.
- a chain terminating reagent e.g., ultraviolet, gamma or X-ray irradiation; ethidium bromide or other intercalators; DNA binding proteins, such as single strand binding proteins
- the partial duplex molecules e.g., containing partially extended chains, are then denatured and reannealed in subsequent rounds of replication or partial replication resulting in polynucleotides which share varying degrees of sequence similarity and which are diversified with respect to the starting population of DNA molecules.
- the products, or partial pools of the products can be amplified at one or more stages in the process.
- Polynucleotides produced by a chain termination method, such as described above, are suitable substrates for any other described recombination format.
- Mutational methods which result in the alteration of individual nucleotides or groups of contiguous or non-contiguous nucleotides can be favorably employed to introduce nucleotide diversity into one or more parental subtilisin homologues.
- Many mutagenesis methods are found in the above-cited references; additional details regarding mutagenesis methods can be found in following, which can also be applied to the present invention.
- error-prone PCR can be used to generate nucleic acid variants.
- PCR is performed under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. Examples of such techniques are found in the references above and, e.g., in Leung et al. (1989) Technique 1:11-15 and Caldwell et al. (1992) PCR Methods Applic. 2:28-33.
- assembly PCR can be used, in a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions can occur in parallel in the same reaction mixture, with the products of one reaction priming the products of another reaction.
- Oligonucleotide directed mutagenesis can be used to introduce site- specific mutations in a nucleic acid sequence of interest. Examples of such techniques are found in the references above and, e.g., in Reidhaar-Olson et al. (1988) Science. 241:53-57. Similarly, cassette mutagenesis can be used in a process that replaces a small region of a double stranded DNA molecule with a synthetic oligonucleotide cassette that differs from the native sequence.
- the oligonucleotide can contain, e.g., completely and/or partially randomized native sequence(s).
- Recursive ensemble mutagenesis is a process in which an algorithm for protein mutagenesis is used to produce diverse populations of phenotypically related mutants, members of which differ in amino acid sequence. This method uses a feedback mechanism to monitor successive rounds of combinatorial cassette mutagenesis. Examples of this approach are found in Arkin & Youvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815.
- Exponential ensemble mutagenesis can be used for generating combinatorial libraries with a high percentage of unique and functional mutants. Small groups of residues in a sequence of interest are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. Examples of such procedures are found in Delegrave & Youvan (1993) Biotechnology Research 11:1548- 1552.
- In vivo mutagenesis can be used to generate random mutations in any cloned DNA of interest by propagating the DNA, e.g., in a strain of E. coli that carries mutations in one or more of the DNA repair pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in one of these strains will eventually generate random mutations within the DNA. Such procedures are described in the references noted above.
- Transformation of a suitable host with such multimers consisting of genes that are divergent with respect to one another, (e.g., derived from natural diversity or through application of site directed mutagenesis, error prone PCR, passage through mutagenic bacterial strains, and the like), provides a source of nucleic acid diversity for DNA diversification, e.g., by an in vivo recombination process as indicated above.
- a multiplicity of monomeric polynucleotides sharing regions of partial sequence similarity can be transformed into a host species and recombined in vivo by the host cell.
- Subsequent rounds of cell division can be used to generate libraries, members of which, include a single, homogenous population, or pool of monomeric polynucleotides.
- the monomeric nucleic acid can be recovered by standard techniques, e.g., PCR and/or cloning, and recombined in any of the recombination formats, including recursive recombination formats, described above.
- Multispecies expression libraries include, in general, libraries comprising cDNA or genomic sequences from a plurality of species or strains, operably linked to appropriate regulatory sequences, in an expression cassette.
- the cDNA and/or genomic sequences are optionally randomly ligated to further enhance diversity.
- the vector can be a shuttle vector suitable for transformation and expression in more than one species of host organism, e.g., bacterial species, eukaryotic cells.
- the library is biased by preselecting sequences which encode a protein of interest, or which hybridize to a nucleic acid of interest. Any such libraries can be provided as substrates for any of the methods herein described.
- recombined CDRs derived from B cell cDNA libraries can be amplified and assembled into framework regions (e.g., Jirholt et al. (1998) "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework” Gene 215: 471) prior to diversifying according to any of the methods described herein.
- framework regions e.g., Jirholt et al. (1998) "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework” Gene 215: 47
- Libraries can be biased towards nucleic acids which encode proteins with desirable enzyme activities. For example, after identifying a clone from a library which exhibits a specified activity, the clone can be mutagenized using any known method for introducing DNA alterations. A library comprising the mutagenized homologues is then screened for a desired activity, which can be the same as or different from the initially specified activity. An example of such a procedure is proposed in Short (1999) U.S. Patent No. 5,939,250 for "Production of Enzymes Having Desired Activities by Mutagenesis.” Desired activities can be identified by any method known in the art.
- WO 99/10539 proposes that gene libraries can be screened by combining extracts from the gene library with components obtained from metabolically rich cells and identifying combinations which exhibit the desired activity. It has also been proposed (e.g., WO 98/58085) that clones with desired activities can be identified by inserting bioactive substrates into samples of the library, and detecting bioactive fluorescence corresponding to the product of a desired activity using a fluorescent analyzer, e.g., a flow cytometry device, a CCD, a fluorometer, or a spectrophotometer.
- a fluorescent analyzer e.g., a flow cytometry device, a CCD, a fluorometer, or a spectrophotometer.
- Libraries can also be biased towards nucleic acids which have specified characteristics, e.g., hybridization to a selected nucleic acid probe.
- a desired activity e.g., an enzymatic activity, for example: a lipase, an esterase, a protease, a glycosidase, a glycosyl transferase, a phosphatase, a kinase, an oxygenase, a peroxidase, a hydrolase, a hydratase, a nitrilase, a transaminase, an amidase or an acylase) can be identified from among genomic DNA sequences in the following manner.
- an enzymatic activity for example: a lipase, an esterase, a protease, a glycosidase, a glycosyl transferase, a phosphatase, a kinase, an oxygenase, a peroxidase
- Single stranded DNA molecules from a population of genomic DNA are hybridized to a ligand-conjugated probe.
- the genomic DNA can be derived from either a cultivated or uncultivated microorganism, or from an environmental sample. Alternatively, the genomic DNA can be derived from a multicellular organism, or a tissue derived therefrom.
- Second strand synthesis can be conducted directly from the hybridization probe used in the capture, with or without prior release from the capture medium or by a wide variety of other strategies known in the art.
- the isolated single-stranded genomic DNA population can be fragmented without further cloning and used directly in, e.g., a recombination-based approach, that employs a single-stranded template, as described above.
- Non-Stochastic methods of generating nucleic acids and polypeptides are alleged in Short “Non-Stochastic Generation of Genetic Vaccines and Enzymes” WO 00/46344. These methods, including proposed non-stochastic polynucleotide reassembly and site-saturation mutagenesis methods be applied to the present invention as well.
- Random or semi-random mutagenesis using doped or degenerate oligonucleotides is also described in, e.g., Arkin and Youvan (1992) "Optimizing nucleotide mixtures to encode specific subsets of amino acids for semi-random mutagenesis" Biotechnology 10:297- 300; Reidhaar-Olson et al. (1991) "Random mutagenesis of protein sequences using oligonucleotide cassettes" Methods Enzvmol. 208:564-86; Lim and Sauer (1991) "The role of internal packing interactions in determining the structure and stability of a protein” J. Mol. Biol.
- Kits for mutagenesis, library construction and other diversity generation methods are also commercially available.
- kits are available from, e.g., Stratagene (e.g., QuickChangeTM site-directed mutagenesis kit; and ChameleonTM double- stranded, site-directed mutagenesis kit), Bio/Can Scientific, Bio-Rad (e.g., using the
- nucleic acids of the invention can be recombined (with each other, or with related (or even unrelated) sequences) to produce a diverse set of recombinant nucleic acids, including, e.g., sets of homologous nucleic acids, as well as corresponding polypeptides.
- the invention also includes compositions comprising two or more polynucleotides of the invention (e.g., as substrates for recombination).
- the composition can comprise a library of recombinant nucleic acids, where the library contains at least 2, 3, 5, 10, 20, or 50 or more, e.g., at least about 100, at least about 1000, at least about 10,000, or more, nucleic acids.
- the nucleic acids are optionally cloned into expression vectors, providing expression libraries.
- the invention also includes compositions produced by digesting one or more polynucleotide of the invention with a restriction endonuclease, an RNAse, or a DNAse (e.g., as is performed in certain of the recombination formats noted above); and compositions produced by fragmenting or shearing one or more polynucleotide of the invention by mechanical means (e.g., sonication, vortexing, and the like), which can also be used to provide substrates for recombination in the methods above.
- compositions comprising sets of oligonucleotides corresponding to more than one nucleic acid of the invention are useful as recombination substrates and are a feature of the invention. For convenience, these fragmented, sheared, or oligonucleotide synthesized mixtures are referred to as fragmented nucleic acid sets.
- compositions produced by incubating one or more of the fragmented nucleic acid sets in the presence of ribonucleotide- or deoxyribonucleotide triphosphates and a nucleic acid polymerase are also included in the invention.
- the nucleic acid polymerase may be an RNA polymerase, a DNA polymerase, or an RNA-directed DNA polymerase (e.g., a "reverse transcriptase”); the polymerase can be, e.g., a thermostable DNA polymerase (such as, VENT, TAQ, or the like).
- subtilisin homologue polypeptides referred to herein as "subtilisin homologue polypeptides" or simply “subtilisin homologues.”
- An isolated or recombinant subtilisin homologue polypeptide of the invention includes a polypeptide comprising a sequence selected from SEQ ID NO: 131 to SEQ ID NO:260, and conservatively modified variations therof.
- subtilisin homologues with enhanced thermal stability reveal a number of variable amino acid positions.
- several features are remarkable (Fig. 2A).
- the vast majority of novel subtilisin homologues with enhanced thermal stability have substituted Arg for Ser99 (all amino acid comparisons are made relative to the mature Savinase® protein), Ala for Asnll4, Asn for Ser 206, and Arg for Thr207.
- Arg for Ser99 all amino acid comparisons are made relative to the mature Savinase® protein
- Ala for Asnll4 Asn for Ser 206
- Arg for Thr207 a cluster of variable residues is observed at positions 209-212.
- the amino acid substitutions at positions 99, 114, 206 and 207 are non-conservative substitutions. pH Shifting
- Asnl98 are found in the majority of subtilisin homologues with activities at altered pH.
- DMF dimethylformamide
- subtilisin homologue polypeptides of the invention are described above.
- the polypeptides may be produced by direct peptide synthesis using solid-phase techniques (Stewart et al. (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San Francisco; Merrifield (1963) J. Am. Chem. Soc. 85:2149-2154).
- Peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with the instructions provided by the manufacturer.
- subsequences may be chemically synthesized separately and combined using chemical methods to provide full-length subtilisin homologues.
- Peptides can also be ordered from a variety of sources.
- subtilisin homologue polypeptide of the invention is used to produce antibodies which have, for example, diagnostic uses, e.g., related to the activity, distribution, and expression of subtilisin homologues.
- Antibodies to subtilisin homologues of the invention may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library.
- Subtilisin homologue polypeptides for antibody induction do not require biological activity; however, the polypeptide or oligopeptide must be antigenic.
- Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least
- subtilisin homologue polypeptide 10 amino acids, preferably at least 15 or 20 amino acids.
- Short stretches of a subtilisin homologue polypeptide may be fused with another protein, such as keyhole limpet hemocyanin, and antibody produced against the chimeric molecule.
- Suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors. See, Huse et al. (1989) Science 246: 1275-1281; and Ward, et al. (1989) Nature 341: 544-546. Specific monoclonal and polyclonal antibodies and antisera will usually bind with a K D of at least about 0.1 ⁇ M, preferably at least about 0.01 ⁇ M or better, and most typically and preferably, 0.001 ⁇ M or better.
- Subtilisin homologue polypeptides of the present invention include conservatively modified variations of the sequences disclosed herein as SEQ ID NO: 131 to SEQ ID NO:260. Such conservatively modified variations comprise substitutions, additions or deletions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than about 5%, more typically less than about 4%, about 2%, or about 1%) in any of SEQ ID NO:131 to SEQ ID NO:260.
- a conservatively modified variation (e.g., deletion) of the 173 amino acid polypeptide identified herein as SEQ ID NO: 131 will have a length of at least 164 amino acids, preferably at least 166 amino acids, more preferably at least 170 amino acids, and still more preferably at least 171 amino acids, corresponding to a deletion of less than about 5%, about 4%, about 2% or about 1%, or less of the polypeptide sequence.
- Another example of a conservatively modified variation e.g., a
- “conservatively substituted variation” of the polypeptide identified herein as SEQ ID NO: 131 will contain “conservative substitutions”, according to the six substitution groups set forth in Table 2 (supra), in up to about 9 residues (i.e., less than about 5%) of the 173 amino acid polypeptide.
- subtilisin polypeptide sequence homologues of the invention can be present as part of larger polypeptide sequences such as occur in a mature subtilisin protease, in a pre-pro subtilisin peptide or upon the addition of one or more domains for purification of the protein (e.g., poly Histidine (His) segments, FLAG tag segments, etc.).
- domains for purification of the protein e.g., poly Histidine (His) segments, FLAG tag segments, etc.
- the additional functional domains have little or no effect on the activity of the subtilisin portion of the protein, or where the additional domains can be removed by post synthesis processing steps such as by treatment with a protease.
- polypeptides of the invention provide a variety of new polypeptide sequences as compared to other subtilisin homologues, the polypeptides also provide new structural features which can be recognized, e.g., in immunological assays.
- the generation of antisera which specifically binds the polypeptides of the invention, as well as the polypeptides which are bound by such antisera, are a feature of the invention.
- the invention includes subtilisin homologue proteins that specifically bind to or that are specifically immunoreactive with an antibody or antisera generated against an immunogen comprising an amino acid sequence selected from one or more of SEQ ID NO: SEQ ID NO: 131 to SEQ ID NO:260.
- subtilisins such as those represented by the proteins or peptides corresponding to GenBank accession numbers available as of April 3, 2000 and exemplified by P29600, P41362, P29599, P27693, P20724, P41363, P00780, P00781, P35835, P00783, P29142, P04189, P07518, P00782, P04072, P16396, P29140, P29139, P08594, P16588, P11018, P54423, P40903, P23314, P23653, P33295, P42780, and P80146.
- accession number corresponds to a nucleic acid
- a polypeptide encoded by the nucleic acid is generated and used for antibody/antisera subtraction purposes.
- the immunoassay uses a polyclonal antiserum which was raised against one or more polypeptide comprising one or more of the sequences corresponding to one or more of : SEQ ID NO: 131 to SEQ ID NO:260, or a substantial subsequence thereof (i.e., at least about 30% of the full length sequence provided).
- the full set of potential polypeptide immunogens derived from SEQ ID NO: 131 to SEQ ID NO:260 are collectively referred to below as "the immunogenic polypeptides.”
- the resulting antisera is optionally selected to have low cross-reactivity against the control subtilisin homologues, other known subtilisin homologues and any such cross-reactivity is removed by immunoabsorbtion with one or more of the control subtilisin homologues, prior to use of the polyclonal antiserum in the immunoassay.
- one or more of the immunogenic polypeptides is produced and purified as described herein.
- recombinant protein may be produced in a bacterial cell line.
- An inbred strain of mice (used in this assay because results are more reproducible due to the virtual genetic identity of the mice) is immunized with the immunogenic protein(s) in combination with a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a standard description of antibody generation, immunoassay formats and conditions that can be used to determine specific immunoreactivity).
- one or more synthetic or recombinant polypeptide derived from the sequences disclosed herein is conjugated to a carrier protein and used as an immunogen.
- Polyclonal sera are collected and titered against the immunogenic polypeptide in an immunoassay, for example, a solid phase immunoassay with one or more of the immunogenic proteins immobilized on a solid support.
- Polyclonal antisera with a titer of 10 6 or greater are selected, pooled and subtracted with the control subtilisin polypeptides, e.g., those identified from GenBank as noted, to produce subtracted pooled titered polyclonal antisera.
- the subtracted pooled titered polyclonal antisera are tested for cross reactivity against the control subtilisin homologues.
- the immunogenic subtilisins are used in this determination, preferably in conjunction with at least two of the control subtilisin homologues, to identify antibodies which are specifically bound by the immunogenic protein(s).
- discriminatory binding conditions are determined for the subtracted titered polyclonal antisera which result in at least about a 5- 10 fold higher signal to noise ratio for binding of the titered polyclonal antisera to the immunogenic subtilisin homologues as compared to binding to the control subtilisin homologues. That is, the stringency of the binding reaction is adjusted by the addition of non-specific competitors such as albumin or non-fat dry milk, or by adjusting salt conditions, temperature, or the like.
- test polypeptides which show at least a 2-5x higher signal to noise ratio than the control polypeptides under discriminatory binding conditions, and at least about a Vi signal to noise ratio as compared to the immunogenic polypeptide(s), shares substantial structural similarity with the immunogenic polypeptide as compared to known subtilisin, and is, therefore a polypeptide of the invention.
- immunoassays in the competitive binding format are used for detection of a test polypeptide.
- cross-reacting antibodies are removed from the pooled antisera mixture by immunoabsorbtion with the control subtilisin polypeptides.
- the immunogenic polypeptide(s) are then immobilized to a solid support which is exposed to the subtracted pooled antisera.
- Test proteins are added to the assay to compete for binding to the pooled subtracted antisera.
- the ability of the test protein(s) to compete for binding to the pooled subtracted antisera as compared to the immobilized protein(s) is compared to the ability of the immunogenic polypeptide(s) added to the assay to compete for binding (the immunogenic polypeptides compete effectively with the immobilized immunogenic polypeptides for binding to the pooled antisera).
- the percent cross-reactivity for the test proteins is calculated, using standard calculations.
- the ability of the control proteins to compete for binding to the pooled subtracted antisera is determined as compared to the ability of the immunogenic polypeptide(s) to compete for binding to the antisera. Again, the percent cross-reactivity for the control polypeptides is calculated, using standard calculations. Where the percent cross-reactivity is at least 5-10x as high for the test polypeptides, the test polypeptides are said to specifically bind the pooled subtracted antisera.
- the immunoabsorbed and pooled antisera can be used in a competitive binding immunoassay as described herein to compare any test polypeptide to the immunogenic polypeptide(s).
- the two polypeptides are each assayed at a wide range of concentrations and the amount of each polypeptide required to inhibit 50% of the binding of the subtracted antisera to the immobilized protein is determined using standard techniques. If the amount of the test polypeptide required is less than twice the amount of the immunogenic polypeptide that is required, then the test polypeptide is said to specifically bind to an antibody generated to the immunogenic protein, provided the amount is at least about 5-10x as high as for a control polypeptide.
- the pooled antisera is optionally fully immunosorbed with the immunogenic polypeptide(s) (rather than the control polypeptides) until little or no binding of the resulting immunogenic polypeptide subtracted pooled antisera to the immunogenic polypeptide(s) used in the immunosorbtion is detectable.
- This fully immunosorbed antisera is then tested for reactivity with the test polypeptide. If little or no reactivity is observed (i.e., no more than 2x the signal to noise ratio observed for binding of the fully immunosorbed antisera to the immunogenic polypeptide), then the test polypeptide is specifically bound by the antisera elicited by the immunogenic protein.
- subtilisin homologues of the invention are favorably used in compositions that serve as cleaning solutions in wide variety of applications, including laundry detergents, contact lens cleansing solutions, and dry cleaning, among others.
- the present invention provides the use of the novel subtilisin homologues of the invention in cleaning and detergent compositions, as well as such compositions containing mutant subtilisin enzymes.
- cleaning and detergent compositions can in principle have any physical form, but the subtilisin homologues are preferably incorporated in liquid detergent compositions or in detergent compositions in the form of bars, tablets, sticks and the like for direct application, wherein they exhibit improved enzyme stability or performance.
- the liquid compositions of the present invention are aqueous liquid detergents having for example a homogeneous physical character, e.g. they can consist of a micellar solution of surfactants in a continuous aqueous phase, so-called isotropic liquids.
- liquid detergents according to the present invention can include an enzyme stabilization system, comprising calcium ion, boric acid, propylene glycol and or short chain carboxylic acids.
- the detergents include additional enzyme components including cellulase, lipases, or proteases.
- powder detergent compositions can include, in addition to any one or more of the subtilisin homologues of the invention as described herein, such components as builders (such as phosphate or zeolite builders), surfactants (such as anionic, cationic, non-ionic or zwitterionic type surfactants), polymers (such as acrylic or equivalent polymers), bleach systems (such as perborate- or amino-containing bleach precursors or activators), structurants (such as silicate structurants), alkali or acid to adjust pH, humectants, and/or neutral inorganic salts.
- builders such as phosphate or zeolite builders
- surfactants such as anionic, cationic, non-ionic or zwitterionic type surfactants
- polymers such as acrylic or equivalent polymers
- bleach systems such as perborate- or amino-containing bleach precursors or activators
- structurants such as silicate structurants
- alkali or acid to adjust pH, humectants, and/or
- the present invention provides computers, computer readable media and - integrated systems comprising character strings corresponding to the sequence information herein for the polypeptides and nucleic acids herein, including, e.g., those sequences listed herein and the various silent substitutions and conservative substitutions thereof.
- GOs genetic algorithms
- homology determination methods have been designed for comparative analysis of sequences of biopolymers, for spell-checking in word processing, and for data retrieval from various databases.
- models that simulate annealing of complementary homologous polynucleotide strings can also be used as a foundation of sequence alignment or other operations typically performed on the character strings corresponding to the sequences herein (e.g., word-processing manipulations, construction of figures comprising sequence or subsequence character strings, output tables, etc.).
- An example of a software package with GOs for calculating sequence similarity is BLAST, which can be adapted to the present invention by inputting character strings corresponding to the sequences herein.
- standard desktop applications such as word processing software
- the integrated systems can include the foregoing software having the appropriate character string information, e.g., used in conjunction with a user interface (e.g., a GUI in a standard operating system such as a Windows, Macintosh or LINUX system) to manipulate strings of characters.
- a user interface e.g., a GUI in a standard operating system such as a Windows, Macintosh or LINUX system
- specialized alignment programs such as BLAST can also be incorporated into the systems of the invention for alignment of nucleic acids or proteins (or corresponding character strings).
- Integrated systems for analysis in the present invention typically include a digital computer with GO software for aligning sequences, as well as data sets entered into the software system comprising any of the sequences herein.
- the computer can be, e.g., a PC (Intel x86 or Pentium chip- compatible DOSTM, OS2TM WINDOWSTM WINDOWS NTTM, WINDOWS95TM, WINDOWS98TM LINUX based machine, a MACINTOSHTM, Power PC, or a UNIX based (e.g., SUNTM work station) machine) or other commercially common computer which is known to one of skill.
- Software for aligning or otherwise manipulating sequences is available, or can easily be constructed by one of skill using a standard programming language such as Visualbasic, Fortran, Basic, Java, or the like.
- Any controller or computer optionally includes a monitor which is often a cathode ray tube ("CRT") display, a flat panel display (e.g., active matrix liquid crystal display, liquid crystal display), or others.
- Computer circuitry is often placed in a box which includes numerous integrated circuit chips, such as a microprocessor, memory, interface circuits, and others.
- the box also optionally includes a hard disk drive, a floppy disk drive, a high capacity removable drive such as a writeable CD-ROM, and other common peripheral elements.
- Inputting devices such as a keyboard or mouse optionally provide for input from a user and for user selection of sequences to be compared or otherwise manipulated in the relevant computer system.
- the computer typically includes appropriate software for receiving user instructions, either in the form of user input into a set parameter fields, e.g., in a GUI, or in the form of preprogrammed instructions, e.g., preprogrammed for a variety of different specific operations.
- the software then converts these instructions to appropriate language for instructing the operation of the fluid direction and transport controller to carry out the desired operation.
- the software can also include output elements for controlling nucleic acid synthesis (e.g., based upon a sequence or an alignment of a sequences herein) or other operations which occur downstream from an alignment or other operation performed using a character string corresponding to a sequence herein.
- kits embodying the methods, composition, systems and apparatus herein optionally comprise one or more of the following: (1) an apparatus, system, system component or apparatus component as described herein; (2) instructions for practicing the methods described herein, and/or for operating the apparatus or apparatus components herein and/or for using the compositions herein; (3) one or more subtilisin composition or component; (4) a container for holding components or compositions, and, (5) packaging materials.
- the present invention provides for the use of any apparatus, apparatus component, composition or kit herein, for the practice of any method or assay herein, and/or for the use of any apparatus or kit to practice any assay or method herein.
- Recombinant, (e.g., shuffled) library sequences corresponding to the diversified region (amino acids 55-227) in the context of Savinase® protease in an expression vector were cloned into a Bacillus 168 apr nprB strain (Harwood and Cutting (1990) Molecular Biological Methods for Bacillus, J. Wiley and Sons, New York) for expression and screening. Activity was compared to that of Savinase®. Genes were sequenced using an Applied Biosystems 310 Sequencer according to the manufacturers directions. Bacillus colonies comprising library produced clearing halos on casein plates were grown to stationary phase in LB medium.
- the supernatant from this medium contained secreted protease and was diluted 100-fold (for pH 5.5 and pH 10 reactions) or 200-fold (for pH 7.5 reactions) into the reaction mixture.
- Protease activities in the culture supernatants were assayed using BODIPY FL casein as a substrate (Jones et al. (1997) Anal Biochem 251: 144). Fluorescence of this multi-fluorophore casein derivative is internally quenched when the protein is intact. Proteolysis causes separation of neighboring fluorophores, relieving quenching, so activity is measured as an increase in fluorescence with time.
- the reaction mixture contained 5 ⁇ g/ml BODIPY FL casein, 1 mM CaCl 2 , and either 50 mM sodium borate (pH 10), 50 mM Tris-HCl (pH 7.5), or 50 mM MES (pH 5.5). All reactions were performed at room temperature for 40-70 minutes. Fluorescence was monitored at 535nm using an excitation wavelength of 485nm (BMG Fluostar). The cv(%) observed for independent determinations with the Savinase® strain was ⁇ 15 under all conditions. All activities are expressed relative to that of Savinase®.
- the pH dependence of the exemplary clones was determined by measuring activity at pH's 5.5, 7.5, and 10. Thermostability was measured as the residual activity at pH 10 after incubation at 70°C for 5 minutes. Function in organic solvent was assayed as activity in 35% DMF at pH 7.5. Representative values are given in Table 3. Assay values obtained for additional clones are provided in Table 4.
- Combinations of properties were evaluated by simultaneously comparing the activities of the recovered clones for pairs of properties. Seventy-seven of the clones demonstrating the highest activity at 23 °C and pHIO were evaluated for the additional properties of residual activity in organic solvent and stablitiy to heat treatment. The seventy-seven clones that were highly active at pH 10 show a broad distribution of properties under these two additional reaction conditions. Enzymes with up to nearly four times more residual after heat treatment or up to 50% greater residual activity in 35% DMF (at pH 7.5) were obtained. Many individuals were also obtained that were both more heat-stable and more active in organic solvent than Savinase® or any of the naturally occurring subtilisins.
- the subtilisin homologue library was tested for combinations of properties by plotting the activities of a large number (i.e., greater than 650) active clones for pairs of properties. Activities are expressed relative to Savinase®. In every case, proteases with higher activities that Savinase® were obtained. For example, Clones 3 A3, 3B3 and 4C6 possess activity levels significantly higher than Savinase® at pHIO, while maintaining heat stability. Other clones show novel activities: 7C6 is active at both pH 10 and pH 5.5; 6A4, 7A2, 4D7 and 5E1 all showed a much greater activity at pH 5.5 than at pHIO as compared to Savinase®.
- the coding sequences shown start at bp 495 and end at bp 1011 relative to a nucleotide sequence encoding the Savinase® subtilisin.
- the amino acid sequences shown start at aa 166 and end at aa 338 of the Savinase® polypeptide.
- the amino acid of the Savinase® polypeptide is shown in SEQ ID NO:261.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT01923084T ATE500323T1 (en) | 2000-04-03 | 2001-04-02 | SUBTILISIN VARIANT |
AU2001249811A AU2001249811B2 (en) | 2000-04-03 | 2001-04-02 | Subtilisin variants |
EP01923084A EP1287123B1 (en) | 2000-04-03 | 2001-04-02 | Subtilisin variant |
DE60144145T DE60144145D1 (en) | 2000-04-03 | 2001-04-02 | Subtilisin variant |
JP2001572961A JP2004508011A (en) | 2000-04-03 | 2001-04-02 | Subtilisin mutant |
AU4981101A AU4981101A (en) | 2000-04-03 | 2001-04-02 | Subtilisin variants |
CA2405063A CA2405063C (en) | 2000-04-03 | 2001-04-02 | Subtilisin variants |
AU2006208427A AU2006208427B2 (en) | 2000-04-03 | 2006-09-08 | Subtilisin variants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19414300P | 2000-04-03 | 2000-04-03 | |
US60/194,143 | 2000-04-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001075087A2 true WO2001075087A2 (en) | 2001-10-11 |
WO2001075087A8 WO2001075087A8 (en) | 2001-12-27 |
WO2001075087A3 WO2001075087A3 (en) | 2002-12-19 |
Family
ID=22716459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010781 WO2001075087A2 (en) | 2000-04-03 | 2001-04-02 | Subtilisin variants |
Country Status (8)
Country | Link |
---|---|
US (4) | US6902922B2 (en) |
EP (1) | EP1287123B1 (en) |
JP (1) | JP2004508011A (en) |
AT (1) | ATE500323T1 (en) |
AU (4) | AU4981101A (en) |
CA (1) | CA2405063C (en) |
DE (1) | DE60144145D1 (en) |
WO (1) | WO2001075087A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004099401A1 (en) * | 2003-05-07 | 2004-11-18 | Novozymes A/S | Variant subtilisin enzymes (subtilases) |
US6902922B2 (en) * | 2000-04-03 | 2005-06-07 | Novozymes A/S | Subtilisin variants |
JP2005534280A (en) * | 2001-12-20 | 2005-11-17 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | Novel alkaline protease derived from Bacillus gibsonii (DSM 14391), and detergent and cleaner containing the novel alkaline protease |
US8785172B2 (en) | 2006-04-20 | 2014-07-22 | Novozymes A/S | Savinase variants having an improved wash performance on egg stains |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
WO2022061210A1 (en) * | 2020-09-21 | 2022-03-24 | Bayer Cropscience Lp | Novel serine proteases |
EP3940050A4 (en) * | 2019-03-11 | 2023-08-02 | Kao Corporation | Mutant protease |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK6488D0 (en) * | 1988-01-07 | 1988-01-07 | Novo Industri As | ENZYMES |
AU2001254622A1 (en) * | 2000-04-28 | 2001-11-12 | Novozymes A/S | Laccase mutants |
US7109016B2 (en) * | 2000-08-21 | 2006-09-19 | Novozymes A/S | Subtilase enzymes |
AU758744B2 (en) * | 2000-10-31 | 2003-03-27 | F. Hoffmann-La Roche Ag | Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain |
DE10121463A1 (en) * | 2001-05-02 | 2003-02-27 | Henkel Kgaa | New alkaline protease variants and washing and cleaning agents containing these new alkaline protease variants |
DK200101090A (en) * | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
ES2336092T3 (en) * | 2002-01-16 | 2010-04-08 | Genencor International, Inc. | VARIANTS OF PROTEASES WITH MULTIPLE SUBSTITUTIONS. |
WO2003062380A2 (en) * | 2002-01-16 | 2003-07-31 | Genencor International, Inc. | Multiply-substituted protease variants |
US7888093B2 (en) * | 2002-11-06 | 2011-02-15 | Novozymes A/S | Subtilase variants |
EP1735433B1 (en) * | 2004-04-02 | 2010-12-08 | Novozymes A/S | Subtilase variants having altered immunogenicity |
US20090060933A1 (en) * | 2004-06-14 | 2009-03-05 | Estell David A | Proteases producing an altered immunogenic response and methods of making and using the same |
US7802883B2 (en) | 2007-12-20 | 2010-09-28 | Johnson & Johnson Vision Care, Inc. | Cosmetic contact lenses having a sparkle effect |
JP2011524166A (en) * | 2008-06-06 | 2011-09-01 | ダニスコ・ユーエス・インク | Compositions and methods comprising mutant microbial proteases |
US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
CA2726850C (en) | 2008-06-13 | 2015-06-02 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
US20110082055A1 (en) * | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
SG179197A1 (en) | 2009-09-18 | 2012-04-27 | Codexis Inc | Reduced codon mutagenesis |
KR20160035587A (en) | 2013-07-10 | 2016-03-31 | 노파르티스 아게 | Multiple proteases deficient filamentous fungal cells and methods of use thereof |
CA2954974A1 (en) | 2014-07-21 | 2016-01-28 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
CN109715793A (en) | 2016-05-05 | 2019-05-03 | 科德克希思公司 | Penicillin-G acylase |
WO2018144679A2 (en) | 2017-02-03 | 2018-08-09 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
MY196740A (en) | 2017-02-13 | 2023-05-03 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
CN110831618B (en) | 2017-04-27 | 2023-08-25 | 科德克希思公司 | Ketoreductase polypeptides and polynucleotides |
AU2018266606A1 (en) | 2017-05-08 | 2019-11-14 | Codexis, Inc. | Engineered ligase variants |
WO2018231462A1 (en) | 2017-06-14 | 2018-12-20 | Codexis, Inc. | Engineered transaminase polypeptides for industrial biocatalysis |
US11643642B2 (en) | 2017-06-27 | 2023-05-09 | Codexis, Inc. | Penicillin-g acylases |
JP2021502068A (en) | 2017-11-07 | 2021-01-28 | コデクシス, インコーポレイテッド | Transglutaminase variant |
US11015180B2 (en) | 2017-12-13 | 2021-05-25 | Codexis, Inc. | Carboxyesterase polypeptides for amide coupling |
EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
SG11202012111UA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered purine nucleoside phosphorylase variant enzymes |
CN112601821A (en) | 2018-07-09 | 2021-04-02 | 科德克希思公司 | Engineered pentose phosphate mutase variant enzymes |
WO2020014048A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered deoxyribose-phosphate aldolases |
KR20210030379A (en) | 2018-07-09 | 2021-03-17 | 코덱시스, 인코포레이티드 | Engineered galactose oxidase mutant enzyme |
US10889806B2 (en) | 2018-07-09 | 2021-01-12 | Codexis, Inc. | Engineered pantothenate kinase variant enzymes |
US11198861B2 (en) | 2018-07-12 | 2021-12-14 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
EP3830106A4 (en) | 2018-07-30 | 2022-07-06 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
SG11202103639SA (en) | 2018-10-29 | 2021-05-28 | Codexis Inc | Engineered dna polymerase variants |
AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
JP2022545718A (en) | 2019-08-30 | 2022-10-28 | コデクシス, インコーポレイテッド | Engineered lipase variants |
WO2021050348A1 (en) | 2019-09-12 | 2021-03-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
CA3165484A1 (en) | 2019-12-20 | 2021-06-24 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
EP4133064A2 (en) | 2020-04-10 | 2023-02-15 | Codexis, Inc. | Engineered transaminase polypeptides |
MX2023002421A (en) | 2020-08-28 | 2023-05-18 | Codexis Inc | Engineered amylase variants. |
JP2023539632A (en) | 2020-08-28 | 2023-09-15 | コデクシス, インコーポレイテッド | Engineered protease variants |
EP4262804A2 (en) | 2020-12-18 | 2023-10-25 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
US20220325285A1 (en) | 2021-04-02 | 2022-10-13 | Codexis, Inc. | ENGINEERED CYCLIC GMP-AMP SYNTHASE (cGAS) VARIANT ENZYMES |
CN117120600A (en) | 2021-04-02 | 2023-11-24 | 科德克希思公司 | Engineered adenylate kinase variant enzymes |
CA3215105A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
IL305922A (en) | 2021-04-02 | 2023-11-01 | Codexis Inc | Engineered guanylate kinase variant enzymes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002618A1 (en) | 1992-07-17 | 1994-02-03 | Gist-Brocades N.V. | High alkaline serine proteases |
WO1995010591A1 (en) | 1993-10-14 | 1995-04-20 | The Procter & Gamble Company | Protease-containing cleaning compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US49827A (en) * | 1865-09-05 | Improvement in machines for making cement pipe | ||
AU620026B2 (en) * | 1987-02-27 | 1992-02-13 | Genencor International, Inc. | Molecular cloning and expression of genes encoding proteolytic enzymes |
DK6488D0 (en) * | 1988-01-07 | 1988-01-07 | Novo Industri As | ENZYMES |
DE69226182T2 (en) * | 1991-05-01 | 1999-01-21 | Novo Nordisk As | STABILIZED ENZYMES AND DETERGENT COMPOSITIONS |
US5340735A (en) * | 1991-05-29 | 1994-08-23 | Cognis, Inc. | Bacillus lentus alkaline protease variants with increased stability |
US5316935A (en) * | 1992-04-06 | 1994-05-31 | California Institute Of Technology | Subtilisin variants suitable for hydrolysis and synthesis in organic media |
ATE217346T1 (en) * | 1992-09-24 | 2002-05-15 | Genencor Int | NEW CLEANING AGENT COMPOSITIONS CONTAINING ALKALINE PROTEASES |
AU1253695A (en) * | 1993-10-14 | 1995-05-04 | Procter & Gamble Company, The | Bleaching compositions comprising protease enzymes |
US5972042A (en) | 1995-12-22 | 1999-10-26 | Novo Nordisk A/S | Method for dyeing a material with a dyeing system which contains an enzymatic oxidizing agent |
US6300116B1 (en) * | 1996-11-04 | 2001-10-09 | Novozymes A/S | Modified protease having improved autoproteolytic stability |
AR015977A1 (en) * | 1997-10-23 | 2001-05-30 | Genencor Int | PROTEASA VARIANTS MULTIPLY SUBSTITUTED WITH ALTERED NET LOAD FOR USE IN DETERGENTS |
US6777218B1 (en) * | 2000-03-14 | 2004-08-17 | Novozymes A/S | Subtilase enzymes having an improved wash performance on egg stains |
ATE500323T1 (en) * | 2000-04-03 | 2011-03-15 | Maxygen Inc | SUBTILISIN VARIANT |
DK200101090A (en) * | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
DE10162728A1 (en) * | 2001-12-20 | 2003-07-10 | Henkel Kgaa | New alkaline protease from Bacillus gibsonii (DSM 14393) and washing and cleaning agents containing this new alkaline protease |
-
2001
- 2001-04-02 AT AT01923084T patent/ATE500323T1/en not_active IP Right Cessation
- 2001-04-02 EP EP01923084A patent/EP1287123B1/en not_active Expired - Lifetime
- 2001-04-02 DE DE60144145T patent/DE60144145D1/en not_active Expired - Lifetime
- 2001-04-02 US US09/824,893 patent/US6902922B2/en not_active Expired - Fee Related
- 2001-04-02 AU AU4981101A patent/AU4981101A/en active Pending
- 2001-04-02 CA CA2405063A patent/CA2405063C/en not_active Expired - Fee Related
- 2001-04-02 WO PCT/US2001/010781 patent/WO2001075087A2/en active Application Filing
- 2001-04-02 JP JP2001572961A patent/JP2004508011A/en active Pending
- 2001-04-02 AU AU2001249811A patent/AU2001249811B2/en not_active Ceased
-
2003
- 2003-12-15 US US10/736,997 patent/US7220566B2/en not_active Expired - Fee Related
-
2006
- 2006-09-08 AU AU2006208427A patent/AU2006208427B2/en not_active Ceased
-
2007
- 2007-04-17 US US11/736,322 patent/US7605115B2/en not_active Expired - Fee Related
-
2009
- 2009-09-18 US US12/562,517 patent/US20100105599A1/en not_active Abandoned
- 2009-12-23 AU AU2009251169A patent/AU2009251169A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002618A1 (en) | 1992-07-17 | 1994-02-03 | Gist-Brocades N.V. | High alkaline serine proteases |
WO1995010591A1 (en) | 1993-10-14 | 1995-04-20 | The Procter & Gamble Company | Protease-containing cleaning compositions |
Non-Patent Citations (3)
Title |
---|
NESS JON E AL, NATURE BIOTECHNOLOGY, vol. 17, no. 9, 1999, pages 893 - 896 |
PATKAR ET AL., CHEM PHYS LIPIDS, vol. 93, 1998, pages 95 |
SHOICHET ET AL., PROC NATL ACAD SCI U S A., vol. 92, pages 452 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7605115B2 (en) | 2000-04-03 | 2009-10-20 | Novozymas Als | Subtilisin variants |
US6902922B2 (en) * | 2000-04-03 | 2005-06-07 | Novozymes A/S | Subtilisin variants |
JP2005534280A (en) * | 2001-12-20 | 2005-11-17 | ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン | Novel alkaline protease derived from Bacillus gibsonii (DSM 14391), and detergent and cleaner containing the novel alkaline protease |
CN102766545A (en) * | 2003-05-07 | 2012-11-07 | 诺维信公司 | Variant subtilisin enzymes (subtilases) |
US7507569B2 (en) | 2003-05-07 | 2009-03-24 | Novozymes A/S | Variant subtilisin enzymes (subtilases) |
AU2004236308B2 (en) * | 2003-05-07 | 2010-09-09 | Maxygen, Inc. | Variant subtilisin enzymes (subtilases) |
WO2004099401A1 (en) * | 2003-05-07 | 2004-11-18 | Novozymes A/S | Variant subtilisin enzymes (subtilases) |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
US8785172B2 (en) | 2006-04-20 | 2014-07-22 | Novozymes A/S | Savinase variants having an improved wash performance on egg stains |
US9200239B2 (en) | 2006-04-20 | 2015-12-01 | Novozymes A/S | Savinase variants having an improved wash performance on egg stains |
EP3940050A4 (en) * | 2019-03-11 | 2023-08-02 | Kao Corporation | Mutant protease |
WO2022061210A1 (en) * | 2020-09-21 | 2022-03-24 | Bayer Cropscience Lp | Novel serine proteases |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Also Published As
Publication number | Publication date |
---|---|
US20070270574A1 (en) | 2007-11-22 |
AU2006208427B2 (en) | 2009-10-01 |
CA2405063C (en) | 2013-06-04 |
AU2006208427A1 (en) | 2006-09-28 |
US20040203130A1 (en) | 2004-10-14 |
US20030049827A1 (en) | 2003-03-13 |
US7605115B2 (en) | 2009-10-20 |
AU2001249811B2 (en) | 2006-06-08 |
AU4981101A (en) | 2001-10-15 |
JP2004508011A (en) | 2004-03-18 |
AU2009251169A1 (en) | 2010-01-21 |
EP1287123A2 (en) | 2003-03-05 |
EP1287123B1 (en) | 2011-03-02 |
DE60144145D1 (en) | 2011-04-14 |
ATE500323T1 (en) | 2011-03-15 |
US20100105599A1 (en) | 2010-04-29 |
US6902922B2 (en) | 2005-06-07 |
US7220566B2 (en) | 2007-05-22 |
WO2001075087A3 (en) | 2002-12-19 |
CA2405063A1 (en) | 2001-10-11 |
WO2001075087A8 (en) | 2001-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6902922B2 (en) | Subtilisin variants | |
AU2001249811A1 (en) | Subtilisin variants | |
US20090298123A1 (en) | Novel Lipase Genes | |
Casey et al. | Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F | |
US6365377B1 (en) | Recombination of insertion modified nucleic acids | |
EP1307548A2 (en) | Novel lipase genes | |
JP2008206519A (en) | Novel glyphosate n-acetyltransferase (gat) gene | |
US20020042055A1 (en) | Alteration of hydrolase genes and screening of the resulting libraries for the ability to catalyze specific reactions | |
US20020155571A1 (en) | Triazine degrading enzymes | |
US20030056245A1 (en) | AP1 amine oxidase variants | |
US7611897B2 (en) | AP1 amine oxidase variants | |
WO2000001718A2 (en) | Ns4a-ns3 catalytic domain of hepatitis c | |
EP1576151A2 (en) | Ap1 amine oxidase variants | |
Roy | Molecular Characterization Of Capsid Protein And Nuclear Inclusion Protein Of Pepper Vein Banding Virus | |
ZA200500910B (en) | AP1 Amine oxidase variants | |
Fox et al. | Development of a protease production platform for structure-based drug design | |
WO2006008654A2 (en) | Rna dependent rna polymerases/primases from coronavirus and their use in molecular biology and drug screening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001249811 Country of ref document: AU Ref document number: IN/PCT/2002/1590/CHE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2001 572961 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405063 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001923084 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2001923084 Country of ref document: EP |